healthevidencedigest

Category: FDA Approvals

This category focuses on FDA approvals for drugs, biologics, and devices. Here you will find clear summaries of each decision, the data behind it, and the clinical context that helps make sense of what the approval means in real world care.

  • The First Oral IL-23 Receptor Blocker for Psoriasis Is FDA-Approved. Here Is What the ICONIC Trial Data Actually Shows.

    The First Oral IL-23 Receptor Blocker for Psoriasis Is FDA-Approved. Here Is What the ICONIC Trial Data Actually Shows.

    📌 The essentials On March 18, 2026, the FDA approved ICOTYDE (icotrokinra, Johnson & Johnson) for the treatment of moderate to severe plaque psoriasis in adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. What makes it mechanistically distinctive: icotrokinra is the first oral peptide that directly blocks the IL-23 receptor, not the IL-23 ligand. All currently approved IL-23-targeting biologics (guselkumab, risankizumab, tildrakizumab) are monoclonal antibodies targeting the IL-23 cytokine itself. Icotrokinra works at the receptor level, introducing a distinct pharmacological approach in an established mechanism. How it is taken: one 200 mg tablet once daily, taken with water upon waking, at least 30 minutes before eating. May be dispersed in water for patients who have difficulty swallowing tablets. Who it is approved for: adults and adolescents aged 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. The clinical basis: the Phase 3 ICONIC clinical development program across five randomized controlled trials enrolling more than 2,500 patients. Key efficacy numbers at week 16 across trials: IGA 0/1 (clear or almost clear skin) approximately 65 to 70%; PASI 90 approximately 50 to 57%. In head-to-head comparisons, icotrokinra showed superiority to deucravacitinib (Sotyktu) on both primary endpoints. At 52 weeks, complete skin clearance (PASI 100) rates increased to 48 to 49% in two pivotal studies.

    Plaque psoriasis is among the most common immune-mediated skin conditions in the world, affecting more than 125 million people globally. It is not primarily a cosmetic problem. The chronic inflammation that drives the characteristic plaques, scaling, and itch also carries systemic consequences: psoriatic arthritis develops in up to 30% of patients, and individuals with moderate to severe disease have elevated cardiovascular risk, increased rates of depression and anxiety, and substantially reduced quality of life.

    The treatment landscape for moderate to severe plaque psoriasis transformed with the arrival of biologics targeting the IL-17 and IL-23 pathways in the 2010s and 2020s. These injectable therapies produce very high rates of skin clearance but require subcutaneous or intravenous administration, carrying an injection burden that affects adherence for some patients. The oral options in this space have been limited: apremilast (Otezla) is a PDE4 inhibitor with more modest efficacy than IL-17 or IL-23 biologics, and deucravacitinib (Sotyktu) targets TYK2 and has shown meaningful but not biologic-comparable clearance rates.

    ICOTYDE (icotrokinra), approved March 18, 2026, enters this landscape as the first oral therapy targeting the IL-23 receptor directly. The efficacy data from the ICONIC program puts it in a different category from prior oral options and, on some measures, in range of biologic-level responses, in a once-daily pill.

    What Icotrokinra Is and How It Works

    IL-23 (interleukin-23) is a cytokine that plays a central role in the inflammatory cascade driving plaque psoriasis. It activates and sustains Th17 cells, the immune cell population that produces IL-17, the downstream cytokine directly responsible for much of the skin inflammation in psoriasis. Blocking IL-23 at any point in this pathway reduces Th17 activation and downstream inflammation.

    Existing IL-23-targeting biologics work by binding to the p19 subunit of the IL-23 cytokine itself, preventing it from activating its receptor. Icotrokinra takes a different approach: it is an oral peptide that binds directly to the IL-23 receptor (IL-23R) on the surface of immune cells, blocking the receptor from receiving the IL-23 signal regardless of how much IL-23 is present. This is mechanistically analogous to blocking the lock rather than confiscating the key.

    The ability to deliver this level of receptor-targeted precision in an oral small molecule format is what makes icotrokinra mechanistically distinctive. It is not a large protein antibody requiring injection. It is a peptide that survives oral ingestion and reaches the target receptor after absorption from the gastrointestinal tract. The pharmacological challenge of engineering peptides that can do this reliably is substantial, which is why icotrokinra is the first of its kind to reach approval.

    How icotrokinra compares to other oral psoriasis treatments Apremilast (Otezla) is an oral PDE4 inhibitor that broadly dampens inflammatory signaling. It produces IGA 0/1 rates of approximately 20 to 30% at 16 weeks and PASI 75 rates of approximately 40% in pivotal trials. It is generally considered a step below biologics in efficacy for moderate to severe disease. Deucravacitinib (Sotyktu) is an oral TYK2 inhibitor that selectively suppresses IL-23 and IL-12 signaling. In its pivotal POETYK PSO-1 and PSO-2 trials, it produced IGA 0/1 rates of 53 to 58% and PASI 75 rates of 58 to 65% at week 24, positioning it meaningfully above apremilast. Icotrokinra produced IGA 0/1 rates of 65 to 70% and PASI 90 rates of 50 to 57% at week 16 across its pivotal trials, with head-to-head superiority demonstrated directly against deucravacitinib in ICONIC-ADVANCE 1 and 2. No head-to-head trial comparing icotrokinra to IL-17 or IL-23 biologics has been completed. Where icotrokinra fits in the treatment hierarchy will be determined by payer formularies, prescriber experience, and individual patient considerations including injection hesitancy, comorbidities, and treatment history.

    The ICONIC Clinical Development Program: What the Data Shows

    The FDA approval is based on five Phase 3 randomized controlled trials collectively enrolling more than 2,500 patients, designated the ICONIC program. The co-primary endpoints across studies were the proportion of patients achieving IGA 0/1 (clear or almost clear skin) with at least a 2-grade improvement, and PASI 90 (at least 90% improvement in psoriasis severity from baseline), both at week 16.

    ICONIC-ADVANCE 1 and 2: the pivotal approval studies with active comparator

    The two pivotal trials supporting the approval are ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), published simultaneously in The Lancet in September 2025. These trials were randomized, double-blind, placebo-controlled and active-comparator-controlled, comparing icotrokinra (200 mg once daily) to both placebo and deucravacitinib (6 mg once daily) in adults with moderate to severe plaque psoriasis.

    Endpoint at Week 16IcotrokinraPlaceboDeucravacitinib
    IGA 0/1 (ADVANCE 1)68% (213/311)11% (17/156)49%
    IGA 0/1 (ADVANCE 2)70% (227/322)9% (7/82)49%
    PASI 90 (ADVANCE 1)55% (171/311)4% (6/156)36%
    PASI 90 (ADVANCE 2)57% (184/322)1% (1/82)38%
    PASI 100 complete clearance (ADVANCE 1, Week 16)~33%Less than 1%~17%
    PASI 100 complete clearance (ADVANCE 2, Week 16)~33%Less than 1%~16%

    Source: Gold et al. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.

    Both coprimary endpoints and all key secondary endpoints were met in each study. Icotrokinra demonstrated statistically significant superiority over deucravacitinib on both IGA 0/1 and PASI 90 at week 16, with treatment differences of approximately 19 to 20 percentage points on IGA 0/1 and approximately 18 to 19 percentage points on PASI 90 versus deucravacitinib. This head-to-head superiority over the most recently approved oral systemic therapy is the most clinically significant efficacy finding in the dataset.

    ICONIC-LEAD: adolescent and adult data

    ICONIC-LEAD (NCT06095115) enrolled 684 participants (456 icotrokinra, 228 placebo) in a 2:1 randomization. This study evaluated both adults and adolescents and provides the specific data supporting the pediatric indication. At week 16, 65% of icotrokinra-treated patients achieved IGA 0/1 versus 8% with placebo (difference 56%; 95% CI 50 to 62%), and 50% achieved PASI 90 versus 4% with placebo (difference 45%; 95% CI 40 to 50%). By week 24, these rates improved to 74% IGA 0/1 and 65% PASI 90.

    ICONIC-TOTAL: high-impact sites

    ICONIC-TOTAL (NCT06095102) specifically enrolled patients with plaque psoriasis affecting high-impact and difficult-to-treat areas including scalp, genitals, and hands/feet. At 52 weeks, 72% of patients with scalp psoriasis achieved scalp-specific IGA 0/1 clearance. Genital and hand/foot clearance rates were similarly high. These difficult-to-treat locations are often where patients report the greatest impact on quality of life and where many existing systemic therapies show lower effectiveness than in non-special site disease.

    52-week durability data

    One-year data from ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD, presented at the 2026 American Academy of Dermatology Annual Meeting in March 2026, showed that response rates continued to improve beyond week 16. PASI 100 (completely clear skin) rates increased from 33 to 41% at week 24 to 48 to 49% at week 52 across the two ADVANCE studies. No new safety signals were identified through 52 weeks of treatment.

    Safety Profile

    Across the ICONIC clinical program, icotrokinra demonstrated what the FDA and independent reviewers characterized as a placebo-like safety profile at week 16, with adverse event rates within 1.1 percentage points of placebo. No new safety signals emerged through 52 weeks of follow-up.

    Common adverse events reported in trials:

    • Headache
    • Nausea
    • Cough
    • Mild fungal infections (predominantly oral candidiasis)
    • Upper respiratory tract infection
    • Fatigue

    Key safety considerations from the prescribing information:

    Tuberculosis screening is required before initiating icotrokinra, consistent with other immunomodulating therapies. Live vaccines should not be administered during treatment. Providers should monitor for signs and symptoms of infection throughout the treatment course.

    The absence of the elevated cardiovascular risk signals observed with some JAK inhibitors, and the absence of the hepatic or hematologic monitoring requirements associated with older systemic therapies like methotrexate, are practical clinical advantages in a patient population that often has cardiovascular comorbidities.

    Dosing and Administration

    • Dose: 200 mg once daily
    • Timing: Upon waking, at least 30 minutes before eating
    • Method: One tablet swallowed with water. For patients who have difficulty swallowing tablets, the tablet may be dispersed in at least 120 mL of water; administration should be completed within 15 minutes of dispersion
    • Who is eligible: Adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy

    Where Icotrokinra Fits in Psoriasis Treatment

    Current treatment guidelines from the American Academy of Dermatology recommend a stepwise approach. Topical therapies are typically first-line for mild disease. Systemic therapy becomes appropriate when topical treatments fail or disease is classified as moderate to severe.

    For systemic therapy, the options now include:

    • Conventional systemic agents: methotrexate, cyclosporine, acitretin. Effective but carry significant monitoring burdens and toxicity profiles
    • Apremilast (Otezla): oral PDE4 inhibitor. Modest efficacy, generally better tolerated than conventional systemic agents
    • Deucravacitinib (Sotyktu): oral TYK2 inhibitor. More effective than apremilast, now demonstrated to be less effective than icotrokinra on primary endpoints
    • Biologic therapies targeting IL-17 or IL-23: highest efficacy class but require injection (ixekizumab, secukinumab, guselkumab, risankizumab, bimekizumab, others)
    • Icotrokinra (ICOTYDE): oral IL-23R peptide. Efficacy on primary endpoints exceeds prior oral options and approaches biologic-level response rates in some analyses

    Icotrokinra’s approval creates a new clinical decision point for prescribers who have patients with moderate to severe disease who prefer or require oral treatment but have not achieved adequate responses on apremilast or deucravacitinib, or who want to avoid injectable biologics.

    Whether icotrokinra will move earlier in the treatment sequence, potentially as first-line systemic therapy, will depend on payer formulary decisions, prescriber adoption patterns, and the results of the ongoing ICONIC-ASCEND trial (NCT06934226), which compares icotrokinra to ustekinumab (an IL-12/23 biologic) and will provide the first direct head-to-head data versus an injectable biologic.

    For Patients

    If you have moderate to severe plaque psoriasis and are currently on a systemic therapy that is not achieving adequate control, or if you have been reluctant to try injectable biologics, icotrokinra adds a clinically meaningful new oral option to the conversation you can have with your dermatologist.

    It is not a replacement for injectable biologics in patients who are doing well on those regimens. It is an alternative for patients for whom oral treatment is preferable, for whom prior oral therapies were insufficient, or who are appropriate candidates for first-line systemic therapy.

    Patient support is available through Johnson & Johnson’s ICOTYDE withMe program, which provides cost assistance options and educational resources. Information on eligibility and enrollment is available at icotyde.com.

    The National Psoriasis Foundation maintains current information on all approved psoriasis treatments, including patient perspectives, treatment decision support tools, and a healthcare provider directory for finding dermatologists with psoriasis expertise. The American Academy of Dermatology’s “Find a Dermatologist” tool is a reliable starting point for patients seeking specialist care.

    For related coverage of first-in-class oral therapies across different conditions in 2026, see our post on Foundayo (orforglipron), the first non-peptide oral GLP-1 receptor agonist approved for weight management, which represents a parallel story of oral formulation innovation changing a treatment landscape previously dominated by injectables.

    Sources

    FDA approval announcement: FDA approves icotrokinra for moderate to severe plaque psoriasis. FDA.gov. March 18, 2026.

    Johnson & Johnson approval press release: FDA Approval of ICOTYDE (icotrokinra) Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis. jnj.com. March 18, 2026.

    ICONIC-ADVANCE 1 and 2 primary publication: Gold LS, Armstrong A, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.

    ICONIC-LEAD 24-week data: Phase 3 Findings Suggest Icotrokinra Effective in Adults, Adolescents with Psoriasis. HCPLive. January 2026.

    52-week data press release: ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile. PRNewswire. March 28, 2026.

    ICONIC-TOTAL scalp/genital data: Icotrokinra long-term results affirm promise in difficult-to-treat scalp and genital psoriasis. JNJ Investor. October 2025.

    Dermatology Times approval coverage: FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis. Dermatology Times. April 2026.

    HMP Global approval summary: FDA Approves Icotyde for Moderate-to-Severe Plaque Psoriasis. HMP Global Learning Network. March 2026.

    Rheumatology Advisor ICONIC-LEAD data: FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis. Rheumatology Advisor. March 2026.

    ICONIC trial registrations: ICONIC-ADVANCE 1 (NCT06143878) | ICONIC-ADVANCE 2 (NCT06220604) | ICONIC-LEAD (NCT06095115) | ICONIC-TOTAL (NCT06095102)

    Deucravacitinib FDA approval: FDA approves deucravacitinib for plaque psoriasis. FDA.gov.

    Apremilast FDA approval: FDA approves apremilast for psoriatic arthritis. FDA.gov.

    IL-23 pathway reference: IL-23 and psoriasis pathogenesis. PMC6429360.

    Biologic therapy review: IL-17 and IL-23 pathway inhibition in psoriasis. PMC7460559.

    Patient resources: National Psoriasis Foundation | AAD Find a Dermatologist | ICOTYDE patient support

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about psoriasis treatment, including whether icotrokinra is appropriate for your situation, should be made in consultation with a board-certified dermatologist who can evaluate your individual disease characteristics, treatment history, and comorbidities.
  • Generic Dapagliflozin Is Here. For 40 Million Americans With Type 2 Diabetes, That’s a Big Deal.

    Generic Dapagliflozin Is Here. For 40 Million Americans With Type 2 Diabetes, That’s a Big Deal.

    📌 The essentials The FDA has approved the first generic versions of dapagliflozin (Farxiga) tablets, the first SGLT2 inhibitor to reach generic status in the United States. Multiple generic manufacturers received approval simultaneously. Available doses: 5 mg and 10 mg tablets. Generic approval covers: type 2 diabetes (glycemic control and cardiovascular risk reduction) and reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and cardiovascular disease or multiple cardiovascular risk factors. The brand-name Farxiga retains additional approved indications (heart failure with preserved ejection fraction, chronic kidney disease) that the generics do not yet carry. Current approximate pricing: brand-name Farxiga runs $550 to $650 per month without insurance; generic dapagliflozin is running approximately $290 to $410 per month with discount coupons (GoodRx, SingleCare) as of April 2026. Confirm current pricing at GoodRx.com/dapagliflozin as prices will continue to change with market competition. Verify therapeutic equivalence: check the FDA Orange Book to confirm which manufacturers have received “AB” ratings, indicating interchangeability.

    If you have been prescribing or taking Farxiga (dapagliflozin) for any length of time, you already know the conversation that tends to come up at refill time: the price. Without insurance, a 30-day supply of brand-name Farxiga runs between $550 and $650 per month. For a medication that many patients need to take daily and indefinitely, that is a meaningful barrier. The FDA’s approval of the first generic versions of dapagliflozin tablets changes that equation.

    Multiple generic manufacturers have received approval simultaneously, and while generic pricing is not always as low as patients hope immediately after launch, the competitive pressure that comes with multiple manufacturers is what ultimately drives costs down. This is how the generic drug system is supposed to work.

    Dapagliflozin: More Than a Diabetes Drug

    Dapagliflozin belongs to a class of medications called SGLT2 inhibitors, short for sodium-glucose cotransporter 2 inhibitors. The mechanism is straightforward: the kidneys normally filter glucose from the blood and then reabsorb almost all of it back into circulation. SGLT2 inhibitors block the transporter protein responsible for that reabsorption, so excess glucose gets excreted in the urine instead. Lower blood glucose, less cardiovascular strain, less kidney filtration burden.

    What made dapagliflozin and its SGLT2 classmates remarkable, and what eventually transformed both cardiology and nephrology practice, was what came out of the cardiovascular outcomes trials that the FDA mandated for all new diabetes drugs after 2008. Researchers expected to show the drugs were not harmful. What they found instead was that they were actively protective: significantly reducing hospitalizations for heart failure and slowing kidney disease progression, even in patients without diabetes.

    The DAPA-HF trial, published in the New England Journal of Medicine in 2019, showed dapagliflozin reduced a composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with heart failure with reduced ejection fraction, including patients who did not have type 2 diabetes. The DAPA-CKD trial showed it reduced risk of a sustained decline in kidney function, end-stage kidney disease, or death from kidney or cardiovascular causes by 39% in patients with chronic kidney disease, again including non-diabetic patients. These were not minor findings. They were class-redefining.

    The indications that dapagliflozin currently carries, and what the generic covers Dapagliflozin’s full FDA-approved indication list includes: type 2 diabetes in adults (glycemic control plus cardiovascular risk reduction); reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors; heart failure with reduced ejection fraction (regardless of diabetes status); heart failure with preserved ejection fraction; and chronic kidney disease in adults at risk of progression. The generic approval currently covers the type 2 diabetes and heart failure hospitalization risk reduction indications specifically. The additional heart failure and CKD indications remain on the brand label but are not yet part of the generic labeling. As the evidence base matures, generic labeling may expand to match. For the complete current list, the FDA prescribing information is the authoritative source.

    Why Generic Approval Matters More for This Drug Than Most

    Type 2 diabetes affects more than 40 million Americans, with 90 to 95% of all diabetes cases falling into this category. It is a condition that disproportionately affects lower-income populations and communities of color, exactly the populations for whom a $600-per-month medication is least accessible.

    Despite its strong evidence base, adoption of SGLT2 inhibitor therapy in clinical practice has remained well below what guidelines recommend, and cost is consistently cited as a primary barrier. A 2025 review in npj Metabolic Health and Disease noted this explicitly, pointing to cost and clinician familiarity as the two main obstacles to uptake of a drug class with clear guideline support for reducing cardiovascular and kidney disease burden.

    Generic availability does not immediately solve the cost problem, but it starts the clock. With discount coupons through services like GoodRx or SingleCare, generic dapagliflozin is currently available in the range of $290 to $410 per month for a 30-day supply, compared to $550 to $650 for the brand. That is a meaningful improvement, though still not cheap. As more manufacturers enter the market over the coming months, prices should continue to fall.

    Current approximate price landscape (30-day supply):

    OptionWithout InsuranceWith Discount Coupon
    Brand-name Farxiga$550 to $650/month~$288 (GoodRx)
    Generic dapagliflozin$400 to $500/month$290 to $410 (GoodRx/SingleCare)
    With commercial insuranceVaries by planCopay $0 to $75 typical
    AZ&Me patient assistancePotentially $0Eligibility required

    AZ&Me is AstraZeneca’s patient assistance program for brand-name Farxiga. Patients who meet income eligibility can receive free medication. Details at azandme.com. Generic dapagliflozin is not covered under this program. Pricing figures are approximate as of April 2026 and subject to change.

    What “Therapeutic Equivalence” Actually Means

    A common question when a generic is approved: is it really the same? The short answer is yes, with a specific technical meaning. The FDA requires generics to demonstrate bioequivalence: they must deliver the same active ingredient in the same form, at the same dose, producing the same blood levels over the same time frame as the brand. The inactive ingredients (fillers, binders, coatings) can differ, which occasionally matters for patients with specific allergies or sensitivities, but the therapeutic effect is required to be equivalent.

    Generics approved under this standard receive an “AB” rating in the FDA’s Orange Book, the Approved Drug Products database, indicating they are interchangeable at the pharmacy level without requiring a new prescription. You can check the Orange Book at accessdata.fda.gov/scripts/cder/ob/ to confirm which manufacturers have received approval and their equivalence rating.

    Safety: The Generic Carries the Same Label

    Generic dapagliflozin carries the same prescribing information, contraindications, warnings, and precautions as brand-name Farxiga. These are worth knowing, particularly for patients or prescribers newer to this drug class.

    Contraindications

    • Known serious hypersensitivity to dapagliflozin or any excipient in the formulation
    • eGFR below the threshold specified in the label for the relevant indication (review the current label for the specific eGFR cutoffs by indication)

    Key warnings to discuss with patients

    Diabetic ketoacidosis (DKA): Can occur even with near-normal blood glucose (euglycemic DKA), a well-documented and sometimes underrecognized risk. Patients should be counseled to hold dapagliflozin before surgery and to recognize DKA symptoms including nausea, vomiting, abdominal pain, fatigue, and difficulty breathing.

    Volume depletion: The osmotic diuretic effect can cause dehydration and hypotension, particularly relevant in older patients or those on diuretics. Assess volume status before initiating in high-risk patients.

    Urinary tract and genital infections: The glucosuria that makes SGLT2 inhibitors effective also creates a more hospitable environment for yeast and bacterial infections. Genital mycotic infections are common, particularly in women. Counsel patients to report symptoms and maintain good hygiene.

    Fournier’s gangrene: A rare but serious necrotizing fasciitis of the genitalia has been reported across the SGLT2 class. Patients with symptoms including pain, tenderness, redness, or swelling in the genital or perineal area should seek immediate care.

    Lower limb amputations: A risk signal first identified with canagliflozin. The signal for dapagliflozin is less clearly established but warrants monitoring in high-risk patients including those with peripheral arterial disease or diabetic neuropathy.

    As the SGLT2 class StatPearls reference notes, despite the substantial clinical advantages of this drug class, therapy requires attention to safety considerations including volume depletion, genital infections, diabetic ketoacidosis, and potential lower extremity complications. These are established safety signals, not new or unexpected findings with the generic.

    A note on perioperative management SGLT2 inhibitors should generally be held before scheduled surgery due to the risk of euglycemic DKA. The recommended hold period varies by guideline. The ADA recommends holding for at least 3 to 4 days prior to major surgery. This is a counseling point worth building into any practice that prescribes dapagliflozin, especially now that more patients may receive it via generic without a specialist involved in initiation.

    The Bigger Picture: Where This Drug Class Is Heading

    Generic dapagliflozin’s arrival coincides with a remarkable moment for this drug class. SGLT2 inhibitors, initially developed as diabetes drugs, have become foundational therapies in cardiology and nephrology, a transformation that has happened faster than almost any comparable pharmacological shift in recent memory.

    The 2024 to 2025 research cycle extended the evidence base further, with large meta-analyses showing benefits in acute myocardial infarction, acute decompensated heart failure, and non-diabetic chronic kidney disease without albuminuria. Trials are now exploring effects on cognitive decline, atrial fibrillation, and liver disease. Next-generation SGLT2-based compounds and dual SGLT1/SGLT2 inhibitors are in Phase II development.

    There is also the Medicare context. Dapagliflozin and empagliflozin were selected as two of the first drugs for price negotiation under the Inflation Reduction Act, with negotiated prices taking effect in 2026. Generic competition and Medicare negotiation happening simultaneously represent an unusual convergence of affordability pressure on a single drug class. If that convergence translates to real-world access, it could meaningfully reduce the burden of undertreated cardiovascular and kidney disease in the populations that carry the highest risk.

    For related coverage on how access to GLP-1 medications is being broadened through higher-dose approvals, see our post on Wegovy HD and the STEP UP trial data. For a parallel access story in diabetes care, our post on GLP-1 medications and PCOS covers how prescribing patterns in metabolic disease are shifting rapidly beyond original approved indications.

    What to Watch Going Forward

    Supply and availability

    As of early 2026, generic manufacturers are still ramping up to full production capacity, which means spotty availability at some pharmacies, particularly in smaller markets. Calling ahead before a patient makes a trip to the pharmacy is practical advice worth passing along. Drug availability search tools like Medfinder can also help patients locate stock in real time.

    Insurance formulary adjustments

    Generic approval often triggers formulary changes. Some insurance plans may shift from covering brand-name Farxiga to preferring the generic, or may adjust tier placement. Patients on Farxiga who are told their insurance no longer covers it or covers it differently should check their updated formulary rather than assume the drug is not covered at all. Generic dapagliflozin should be therapeutically equivalent and typically at lower cost.

    Expanding indications for the generic

    The current generic approval covers type 2 diabetes and heart failure hospitalization risk reduction. As the evidence base continues to mature for heart failure with preserved ejection fraction and chronic kidney disease, it is worth watching whether FDA labeling for generic dapagliflozin expands to match the brand’s full approved indications.

    Sources

    FDA announcement: FDA Approves First Generic Dapagliflozin Tablets. FDA.gov.

    Farxiga original FDA approval (T2D/CV): FDA approves dapagliflozin to reduce risk of hospitalization for heart failure in adults. FDA.gov.

    Farxiga full prescribing information: Dapagliflozin prescribing information. accessdata.fda.gov.

    Orange Book: FDA Approved Drug Products with Therapeutic Equivalence Evaluations. accessdata.fda.gov.

    FDA generic drug bioequivalence: Generic Drug Facts. FDA.gov.

    DAPA-HF trial: McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008.

    DAPA-CKD trial: Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-1446.

    SGLT2 inhibitor class reference: Padda IS et al. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. StatPearls. Updated September 2025.

    Next-generation SGLT2 compounds: Cohen TD et al. Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives. Biomedicines. 2026;14(1):81.

    Access barriers review: SGLT2 inhibitors across various patient populations in the era of precision medicine. npj Metabolic Health and Disease. 2025.

    Inflation Reduction Act Medicare negotiation: Medicare Drug Price Negotiation. CMS.gov.

    FDA cardiovascular outcomes trial guidance: Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies. FDA.gov.

    Fournier’s gangrene safety communication: FDA Drug Safety Communication: Rare but serious infection of the genitals and area around them. FDA.gov.

    ADA perioperative guidance: Diabetes Care in the Hospital. ADA Standards of Care 2023.

    Pricing tools: GoodRx: dapagliflozin | SingleCare: dapagliflozin

    Patient assistance: AstraZeneca AZ&Me Program. azandme.com.

    CDC type 2 diabetes: Type 2 Diabetes. CDC.gov.

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Drug pricing information reflects approximate figures at time of publication and is subject to change. Always consult a qualified healthcare provider or pharmacist regarding medication decisions, including decisions about switching from a brand-name product to its generic equivalent.
  • That Itch That Won’t Quit: Inside the FDA Approval That PBC Patients Have Been Waiting For

    That Itch That Won’t Quit: Inside the FDA Approval That PBC Patients Have Been Waiting For

    📌 The essentials On April 22, 2026, the FDA approved Lynavoy (linerixibat, GSK), an oral ileal bile acid transporter (IBAT) inhibitor, for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This is the first FDA-approved therapy specifically indicated for cholestatic pruritus in PBC. It is a full approval, not accelerated, meaning the FDA reviewed actual clinical benefit data. The clinical basis: the Phase 3 GLISTEN trial (NCT03706547) enrolling 238 patients with moderate to severe cholestatic pruritus, showing statistically significant reduction in worst itch NRS score versus placebo (p less than 0.001), with rapid onset by week 2 and benefit sustained through 24 weeks. Sleep quality also improved significantly (p=0.024). Key safety consideration: diarrhea occurred in 61% of patients in GLISTEN, the majority mild to moderate. Discontinuation rate due to diarrhea was approximately 4%. What it does not do: Lynavoy is not a disease-modifying therapy for PBC. It does not slow liver disease progression or replace existing PBC treatments including UDCA or obeticholic acid. It treats the itch.

    There is a particular kind of suffering that does not show up well on a lab report. Cholestatic pruritus, the relentless, internal itch caused by bile acid accumulation in primary biliary cholangitis, is one of them. It does not scratch away. It does not respond to antihistamines. It keeps patients awake at 3 a.m., disrupts concentration, and compounds the psychological weight of already managing a progressive autoimmune liver disease.

    On April 22, 2026, the FDA approved Lynavoy (linerixibat), GSK’s oral IBAT inhibitor, specifically for cholestatic pruritus in adults with PBC. It is the first medicine approved in the United States for this indication. As approvals go, this is one where the clinical evidence and the patient need are unusually well-aligned.

    What Is Primary Biliary Cholangitis?

    PBC is a rare, chronic autoimmune liver disease in which the immune system mistakenly attacks the small bile ducts inside the liver. As those ducts are damaged and scarred over time, bile cannot drain properly; it backs up into the liver and eventually into the bloodstream.

    The disease affects roughly 1 in 1,000 women over 40, though it is underdiagnosed and can affect men as well. Without effective management, PBC can progress to cirrhosis, liver failure, and the need for transplantation.

    Cholestatic pruritus affects up to 89% of people with PBC at some point during the disease. It is caused by the accumulation of bile acids in the skin and blood, and it is notoriously difficult to treat. Before Lynavoy, available options were largely off-label, inconsistently effective, and sometimes poorly tolerated. For many patients, managing the itch meant cycling through treatments that did not really work.

    How Linerixibat Works

    Linerixibat is an ileal bile acid transporter (IBAT) inhibitor. Under normal circumstances, the IBAT protein in the small intestine reabsorbs bile acids from the gut back into circulation, a recycling loop that keeps the body’s bile acid pool stocked. In PBC, where the liver is already struggling to process that pool, this recycling makes the problem worse.

    Linerixibat blocks the IBAT pump in the gut, preventing that reabsorption. Fewer bile acids recirculate. Levels in the blood and skin drop. And for many patients, so does the itch.

    It is a targeted, mechanistically rational approach. Because it acts locally in the gut rather than systemically, it avoids some of the side effects associated with older therapies like cholestyramine.

    Why does blocking gut bile acid recycling help with itch in the skin? Bile acids that recirculate from the gut end up in systemic blood, and from there accumulate in peripheral tissues including the skin. The exact mechanism by which bile acids trigger itch is not fully established; it likely involves bile acid receptors on sensory nerve fibers, specifically the TGR5 receptor and the bile acid-sensitive ion channel TRPA1. The clinical correlation between bile acid levels and itch severity is well-documented. Reducing the circulating load through IBAT inhibition targets the source of the symptom rather than suppressing the itch signal downstream.

    The GLISTEN Trial: What the Data Shows

    The pivotal GLISTEN Phase 3 trial (NCT03706547) enrolled 238 patients with PBC and moderate to severe cholestatic pruritus. Participants were randomized to linerixibat or placebo for 24 weeks. The primary endpoint was itch intensity, measured using the Numerical Rating Scale (NRS) for worst itch, a validated patient-reported outcome that captures what patients actually experience rather than a laboratory surrogate.

    EndpointResultStatistical significance
    Worst itch NRS reduction vs. placeboStatistically significant mean differencep less than 0.001
    Sleep quality improvement (NRS)Significant improvement vs. placebop=0.024
    Onset of itch benefitDetectable by week 2—
    Duration of benefitSustained through 24 weeks—
    Diarrhea (all grade)61% in linerixibat armDiscontinuation rate ~4%
    Abdominal pain18% in linerixibat armDiscontinuation rate less than 1%

    Source: GLISTEN Phase 3 trial, NCT03706547. GSK press release, April 22, 2026.

    The sleep quality finding deserves equal weight as the itch reduction data. In qualitative research and patient surveys, pruritus-related sleep disruption consistently ranks as one of the most burdensome aspects of PBC, sometimes more so than concerns about disease progression. A therapy that demonstrably improves both itch intensity and sleep quality is addressing the full clinical picture of what patients report as most disruptive to their daily lives.

    The diarrhea rate of 61% is notable and warrants clear communication with patients before initiating therapy. Most cases were mild to moderate, and the discontinuation rate of approximately 4% was low, but this is a side effect that will affect real-world tolerability, particularly for patients who are already managing fatigue and GI sensitivity as part of their PBC picture. Clinicians prescribing Lynavoy will need to set expectations carefully and discuss management strategies, including dose timing, dietary considerations, and when dose adjustment is appropriate.

    The full approval status matters here. This is not accelerated approval based on a surrogate biomarker. The FDA reviewed patient-reported outcome data on actual symptom reduction and determined it met the standard for substantial evidence of clinical benefit. That is a meaningful regulatory bar, and the GLISTEN data cleared it.

    Dr. Christopher Bowlus, Chief of Gastroenterology and Hepatology at UC Davis Health and a principal investigator in the linerixibat program, characterized the approval as representing an important opportunity to improve the lives of people with PBC who struggle with uncontrolled and often debilitating pruritus. That framing reflects the clinical reality: “uncontrolled and often debilitating” is not hyperbole in this patient population.

    What This Approval Does Not Answer

    Does treating the itch affect disease progression?

    Lynavoy is approved specifically for symptom management, not as a disease-modifying therapy for PBC itself. Patients with PBC who need a medication to slow liver disease progression are managed with ursodeoxycholic acid (UDCA) or obeticholic acid. Linerixibat does not replace those. Whether there is any long-term hepatoprotective effect from reducing bile acid recirculation has not been established and should not be assumed from the GLISTEN data, which was not designed or powered to assess disease progression.

    Real-world tolerability

    Trial populations tend to be healthier and more closely monitored than the broader patient population. The 61% diarrhea rate in GLISTEN will bear watching in post-market use, particularly in older patients or those with baseline GI sensitivity who were not well represented in the trial. Patient registries and observational data over the next one to two years will be more informative here than the trial data alone.

    Cost and access

    Lynavoy carries Orphan Drug Designation, which typically supports premium pricing and seven years of market exclusivity. GSK has not yet announced U.S. list pricing. For a symptom-focused therapy in a rare disease, the cost-benefit calculus for payers is different than for a life-prolonging treatment, which could create coverage access hurdles worth monitoring. GSK’s patient support program details will matter significantly for patients navigating these conversations.

    The Broader Context: IBAT Inhibitors and Cholestatic Liver Disease

    Linerixibat’s approval in adult PBC is part of a broader story in hepatology. The IBAT inhibitor mechanism has already demonstrated clinical utility in pediatric cholestatic conditions. Maralixibat (Livmarli) is approved for cholestatic pruritus in Alagille syndrome, and odevixibat (Bylvay) is approved for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC). The validation of this mechanism in adult PBC extends the evidence base for IBAT inhibition across cholestatic conditions and may support future investigation in other forms of cholestatic liver disease where pruritus remains inadequately managed.

    Lynavoy is also GSK’s first FDA-approved liver medicine from its hepatology pipeline, reflecting a deliberate strategic move for a company historically stronger in respiratory and immunology. A partnership with Alfasigma S.p.A. covers global commercialization, with regulatory submissions underway in the EU, UK, Canada, and China. Whether this represents a durable GSK hepatology platform or a single-indication program will become clearer as the pipeline matures.

    For context on how the FDA approaches safety monitoring for rare disease liver conditions, see our coverage of the Tavneos (avacopan) serious liver injury warning and the ongoing regulatory dispute between the FDA and Amgen over voluntary withdrawal.

    For Patients and Caregivers

    For adults living with PBC and cholestatic pruritus who have not achieved adequate itch relief with currently available treatments, Lynavoy adds the first indication-specific approved option in the United States. The conversation about whether it is appropriate for an individual patient belongs with a gastroenterologist or hepatologist who is familiar with the full picture of disease activity, current medications, and GI tolerance.

    The PBCers Organization is the primary U.S. patient advocacy group for primary biliary cholangitis and has responded to the Lynavoy approval as a significant step forward for those dealing with chronic, uncontrolled itch. Their resources, community forums, and physician directory are the best starting point for patients navigating this diagnosis. The American Liver Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases also maintain current clinical information on PBC management.

    The GLISTEN trial is complete. Ongoing clinical trials for PBC and cholestatic liver disease can be searched at ClinicalTrials.gov for patients interested in research participation.

    Sources

    GSK FDA approval press release: GSK Announces U.S. FDA Approval of Lynavoy (linerixibat), the First and Only Medicine Approved in the US Specifically for Cholestatic Pruritus in Adults with Primary Biliary Cholangitis (PBC). April 22, 2026. gsk.com.

    GLISTEN trial registration: NCT03706547. A Phase III Study to Evaluate the Efficacy and Safety of Linerixibat in Participants with Primary Biliary Cholangitis with Cholestatic Pruritus. ClinicalTrials.gov.

    PBC epidemiology and pruritus burden: Primary Biliary Cholangitis: Epidemiology and Quality of Life. PMC7510845.

    Cholestatic pruritus overview: Cholestatic Pruritus. StatPearls. NCBI.

    IBAT inhibitor mechanism: Ileal Bile Acid Transporter Inhibitors as a Novel Therapeutic Approach. PMC7387516.

    UDCA in PBC: Ursodeoxycholic Acid. StatPearls. NCBI.

    Obeticholic acid FDA approval: FDA approves obeticholic acid for primary biliary cholangitis. FDA.gov.

    Maralixibat FDA approval: FDA approves maralixibat chloride for Alagille syndrome. FDA.gov.

    Odevixibat FDA approval: FDA approves odevixibat for pruritus in cholestatic liver disease. FDA.gov.

    PBC NIDDK overview: Primary Biliary Cholangitis. NIDDK.

    Orphan Drug Designation: Designating an Orphan Product. FDA.gov.

    Patient resources: PBCers Organization | American Liver Foundation: PBC | NIDDK PBC | ClinicalTrials.gov: PBC pruritus

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about PBC treatment, including whether linerixibat is appropriate for your situation, should be made in consultation with a qualified gastroenterologist or hepatologist familiar with your individual disease status, treatment history, and current medications.

  • Ovarian Cancer Has Resisted Almost Every Drug Thrown at It in the Platinum-Resistant Setting. Lifyorli™ Just Changed That by Targeting Cortisol.

    Ovarian Cancer Has Resisted Almost Every Drug Thrown at It in the Platinum-Resistant Setting. Lifyorli™ Just Changed That by Targeting Cortisol.

    📌 The essentials On March 25, 2026, the FDA approved Lifyorli (relacorilant, Corcept Therapeutics) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval based on overall survival data, not accelerated approval. The mechanism: relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist. It blocks cortisol’s tumor-protective action that suppresses apoptosis in cancer cells, sensitizing them to nab-paclitaxel’s cytotoxic effect. Dosing: relacorilant 150 mg orally on the day before, day of, and day after each nab-paclitaxel infusion, given in 28-day cycles. The clinical basis: Phase 3 ROSELLA trial (NCT05257408), published in The Lancet, showing median overall survival of 16.0 versus 11.9 months (HR 0.65; p=0.0004), a 35% reduction in risk of death. The 18-month OS rate was 46% versus 27%. NCCN has designated relacorilant plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer.

    For roughly thirty years, the story of platinum-resistant ovarian cancer has been one of persistent failure. Trial after trial. Checkpoint inhibitor after checkpoint inhibitor. PARP inhibitor combinations. Antibody-drug conjugates. Antiangiogenics beyond bevacizumab. The disease has resisted almost everything, and the graveyard of Phase 3 trials that failed in this setting is long and dispiriting.

    Platinum-resistant ovarian cancer is defined by a clinical reality: the cancer progresses within six months of completing platinum-based chemotherapy. At that point, the treatment options narrow sharply. Single-agent non-platinum chemotherapy, including pegylated liposomal doxorubicin, paclitaxel, gemcitabine, and topotecan, with or without bevacizumab, has been the mainstay. Response rates are modest. Survival is poor.

    On March 25, 2026, the FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is the first FDA-approved selective glucocorticoid receptor antagonist, a category of drug that does not target the tumor directly, but instead targets the role cortisol plays in helping tumors resist the chemotherapy meant to kill them. The pivotal ROSELLA trial, published simultaneously in The Lancet, delivered something this disease has not seen in a long time: a statistically robust overall survival improvement.

    The Disease: Why Platinum-Resistant Ovarian Cancer Is So Hard to Treat

    Ovarian cancer is the most lethal gynecologic malignancy. In 2024, an estimated 320,000 new cases were diagnosed globally and approximately 210,000 women died from the disease, accounting for about 4.8% of all cancer-related mortality. In the United States, ovarian cancer kills approximately 12,800 women annually. The high mortality relative to incidence reflects a disease that is typically diagnosed at advanced stage (III or IV), when cure is unlikely.

    Platinum-based chemotherapy, carboplatin and cisplatin, has been the backbone of ovarian cancer treatment for three decades. Most patients initially respond well. The problem is recurrence: approximately 70% of patients with advanced ovarian cancer will relapse, and through successive platinum cycles, resistance becomes inevitable. Once a patient’s cancer progresses within six months of the last platinum regimen, they are classified as platinum-resistant, and the therapeutic landscape changes dramatically for the worse.

    Why this setting has been so difficult: the failed trials The list of Phase 3 trials that failed to improve overall survival in platinum-resistant ovarian cancer is extensive. Checkpoint inhibitors have largely disappointed in ovarian cancer despite transforming outcomes in melanoma, lung cancer, and other solid tumors. The ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab versus chemotherapy, was negative. The underlying biology is partially explanatory: ovarian tumors often have immunosuppressive microenvironments with low T-cell infiltration, limited PD-L1 expression, and mechanisms that actively exclude immune cells. Notably, the ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab plus paclitaxel plus or minus bevacizumab in platinum-resistant ovarian cancer did ultimately produce the first significant PFS and OS benefit with immunotherapy in this setting. That approval, covered here on Health Evidence Digest, required PD-L1 CPS of 1 or higher for the indicated population. For patients who do not meet that biomarker threshold or who have progressed after immunotherapy, the unmet need remained enormous. What was needed for that broader population was a different angle of attack entirely.

    The Mechanism: Cortisol as a Shield for Tumor Cells

    The biological rationale for relacorilant starts with a question that oncologists have long observed but had limited tools to address: why does chemotherapy work initially in ovarian cancer, then stop working? Part of the answer involves the tumor microenvironment, and specifically the role cortisol plays within it.

    Cortisol is a glucocorticoid hormone produced by the adrenal glands that regulates stress responses, inflammation, and immune function. In normal physiology, cortisol plays many important and beneficial roles. In tumor biology, however, cortisol, acting through the glucocorticoid receptor (GR) expressed in many cancer cell types, contributes to chemotherapy resistance through a specific and well-characterized mechanism: it inhibits apoptosis.

    Apoptosis is programmed cell death, the cellular self-destruct mechanism that chemotherapy is specifically designed to trigger. Taxane chemotherapies like nab-paclitaxel work by disrupting microtubule function during cell division, causing mitotic arrest and ultimately apoptotic cell death. When cortisol activates GR signaling in tumor cells, it suppresses the apoptotic machinery, effectively giving those cells a cortisol-mediated shield against the chemotherapy that should be killing them.

    Relacorilant is an oral, selective glucocorticoid receptor antagonist. It competes with cortisol at the GR binding site, blocking the receptor without activating it. With GR signaling suppressed, cortisol’s protection of tumor cells from apoptosis is reduced, and the tumor cells become more sensitive to nab-paclitaxel’s intended mechanism. Relacorilant is selective: it binds only to the glucocorticoid receptor, not to the progesterone, androgen, mineralocorticoid, or estrogen receptors. This selectivity is what distinguishes it from older, non-selective glucocorticoid antagonists like mifepristone.

    The dosing schedule and why it matters for tolerability Relacorilant is taken orally at 150 mg on three specific days per 28-day cycle: the day before each nab-paclitaxel infusion, the day of the infusion, and the day after. Nab-paclitaxel is administered intravenously on days 1, 8, and 15 of each cycle. This intermittent dosing design is intentional. Continuous glucocorticoid receptor blockade would interfere with the body’s normal cortisol-dependent functions, including immune regulation, glucose metabolism, and stress response. By limiting GR blockade to the three days surrounding each chemotherapy infusion, the regimen specifically targets the period when cortisol’s tumor-protective effects are most relevant, while minimizing disruption to normal physiology. This design choice is supported by the trial’s safety data: no cases of adrenal insufficiency were reported in the ROSELLA trial.

    The ROSELLA Trial: Design and Full Results

    The Phase 3 ROSELLA trial (NCT05257408) was an international, randomized, controlled, open-label study conducted across 117 sites in 14 countries, including the United States, multiple European nations, South Korea, Brazil, Argentina, Canada, and Australia, in collaboration with the GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG. Enrollment ran from January 2023 to April 2024.

    Patient population

    Eligible patients were adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, defined as disease progression within six months of the last platinum-based therapy. All had received one to three prior systemic therapy regimens, and all had prior bevacizumab exposure. Patients requiring chronic corticosteroids were excluded. The median patient age was 61 to 62 years.

    Randomization and treatment

    381 patients were randomized 1:1 to relacorilant 150 mg plus nab-paclitaxel 80 mg/m² (n=188), or nab-paclitaxel alone at 100 mg/m² (n=193). The monotherapy arm received a higher dose of nab-paclitaxel to reflect the absence of a chemo-sensitizing partner. The dual primary endpoints were progression-free survival (PFS) by RECIST 1.1 and blinded independent central review, and overall survival.

    Results

    EndpointRelacorilant plus nab-paclitaxelNab-paclitaxel alone
    Median overall survival16.0 months (95% CI 13.0 to 18.3)11.9 months (95% CI 10.0 to 13.8)
    OS hazard ratio0.65 (95% CI 0.51 to 0.83)Reference
    OS p-value0.0004—
    Reduction in risk of death35%—
    12-month OS rate60%50%
    18-month OS rate46%27%
    Median PFS (BICR)6.5 months (95% CI 5.6 to 7.4)5.5 months (95% CI 3.9 to 5.9)
    PFS hazard ratio0.70 (95% CI 0.54 to 0.91)Reference
    PFS p-value0.0076—
    Reduction in risk of progression30%—
    12-month PFS rate25%13%
    Second PFS (PFS2) hazard ratio0.73 (p=0.0037)Reference

    Source: Olawaiye AB et al. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9. ROSELLA trial (NCT05257408).

    The OS data maturity at the final analysis was 76%, meaning three-quarters of patients had experienced the endpoint, making this a robust and interpretable dataset. The Lancet publication notes that the Kaplan-Meier survival curves show progressively widening separation over time, suggesting durable benefit rather than early separation that converges. The 18-month OS rate difference — 46% versus 27% — is particularly striking: at 18 months, nearly half of patients on the combination were still alive, compared with just over one-quarter on chemotherapy alone.

    The benefit was consistent across all prespecified subgroups, including patients who had received two versus three prior lines of therapy, those with prior PARP inhibitor exposure, and across geographic regions. No biomarker selection was required for eligibility or benefit, which means the improvement applies to the broad platinum-resistant ovarian cancer population, not a molecularly defined subset.

    The principal investigator of the ROSELLA trial, Dr. Alexander B. Olawaiye, MD, Director of Gynecologic Cancer Research at Magee-Womens Hospital of UPMC, characterized the finding at the SGO Late-Breaker presentation as the first demonstration that modulating the steroid receptor pathway, specifically the glucocorticoid receptor, can produce benefit in the treatment of platinum-resistant ovarian cancer, noting that the uniqueness of the pathway makes this new in every way.

    Safety: What the Data Shows

    The combination arm had a higher rate of grade 3 or higher treatment-emergent adverse events than the monotherapy arm: 74.5% versus 59.5%. The primary driver was hematologic toxicity, particularly neutropenia (44% versus 25% in the combination arm) and anemia (18% versus 9%). These findings reflect the addition of any chemotherapy-sensitizing agent and are consistent with what clinicians encounter in other combination regimens.

    Adverse event (20% or higher incidence)Combination armMonotherapy arm
    Decreased hemoglobinMost common, all gradesLower rate
    Neutropenia (grade 3 or higher)44%25%
    Fatigue20% or higherPresent
    Nausea20% or higherPresent
    Diarrhea20% or higherPresent
    Decreased platelets20% or higherPresent
    Rash20% or higherPresent
    Decreased appetite20% or higherPresent
    Anemia (grade 3 or higher)18%9%
    Adrenal insufficiency0 cases0 cases
    Deaths attributed to relacorilant00

    Two specific safety findings deserve emphasis. First, no cases of adrenal insufficiency were observed, validating the intermittent dosing design. Second, peripheral neuropathy, a known concern with taxane chemotherapy, occurred at similar rates in both arms, suggesting relacorilant did not worsen this chemotherapy-related toxicity.

    The prescribing label carries a contraindication for patients who require corticosteroids for a life-saving indication, because GR blockade would impair their effectiveness. Patients on systemic corticosteroids for severe asthma, inflammatory bowel disease, or immunosuppression following transplant require careful evaluation before initiating Lifyorli. Prescribing information warnings include neutropenia and severe infection risk, adrenal insufficiency monitoring, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.

    What This Approval Represents

    The NCCN Clinical Practice Guidelines in Oncology added Lifyorli plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer following the approval. That designation reflects the committee’s assessment that the overall survival data from ROSELLA represents a meaningful advance for a patient population with very limited meaningful advances over the past decade.

    Three aspects of the ROSELLA data deserve specific emphasis as markers of robustness. The OS analysis is mature: 76% data maturity is high for an ongoing survival analysis and ensures the hazard ratio estimate is reliable. Subsequent therapies were balanced between the two arms, ruling out the possibility that post-progression treatment differences explain the survival benefit. And the benefit was consistent across all predefined subgroups, including those heavily pretreated and those with prior PARP inhibitor exposure.

    What we do not yet know: open questions for clinical practice No biomarker predicted response. ROSELLA enrolled without biomarker selection and found benefit across all subgroups. That is good news for broad access, but it means there is not yet a way to identify which patients are most likely to respond, or whether some patients have particularly high GR expression that drives greater benefit. Corcept and academic collaborators are likely studying this as a post-approval research question. Patient-reported quality of life. The ROSELLA trial included EORTC quality-of-life measures as secondary endpoints. Full patient-reported outcome analysis had not been comprehensively presented at time of writing. For patients in this setting, tolerability and quality of remaining life matter alongside survival data. Relacorilant in other tumor types. Corcept has active or planned trials of relacorilant in platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, pancreatic cancer, and prostate cancer. The proof-of-concept from ROSELLA that GR antagonism can sensitize tumors to chemotherapy may accelerate these programs.

    Regulatory Status and Access

    FDA approval

    Approved March 25, 2026, for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval, based on overall survival data from ROSELLA meeting both co-primary endpoints.

    European Medicines Agency

    Corcept has submitted a Marketing Authorisation Application (MAA) to the EMA for relacorilant in platinum-resistant ovarian cancer. Relacorilant has received orphan drug designation from the European Commission for ovarian cancer treatment. The EMA review is ongoing.

    Patient support

    Corcept has established Lifyorli Support for patients and healthcare providers at 1-855-439-6754 (1-85-LIFYORLI). For questions about eligibility, prior authorization support, or financial assistance programs, this is the recommended first contact.

    For patients and families navigating platinum-resistant ovarian cancer, the Ovarian Cancer Research Alliance and the Foundation for Women’s Cancer both maintain updated treatment information, clinical trial directories, and peer support resources. For related HED coverage of ovarian cancer treatment advances in 2026, see our post on pembrolizumab becoming the first approved immunotherapy for platinum-resistant ovarian cancer and our analysis of vepdegestrant and the PROTAC mechanism in breast cancer as examples of how novel mechanisms of action are reshaping gynecologic and breast oncology in the same period.

    Sources

    FDA approval: FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA.gov. March 25, 2026.

    Corcept press release (approval): FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist. ir.corcept.com. March 25, 2026.

    Corcept press release (SGO/OS data): Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet. ir.corcept.com. April 10, 2026.

    Primary OS publication: Olawaiye AB et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9

    PFS publication: Lorusso D et al. ROSELLA: a phase 3 study of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. The Lancet. 2025;405:2205-2216.

    ROSELLA trial registration: NCT05257408. ClinicalTrials.gov.

    CancerNetwork OS coverage: Relacorilant/Nab-Paclitaxel Reduces Risk of Death by 35% in Platinum-Resistant Ovarian Cancer. cancernetwork.com. April 2026.

    CURE coverage: Lifyorli Combo Approved in Platinum-Resistant Ovarian Cancer. curetoday.com. March 2026.

    Targeted Oncology: Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer. targetedonc.com. April 2026.

    PROC treatment landscape: Current Treatments, Future Strategies for Platinum-Resistant Ovarian Cancer. AJMC. March 2026.

    PROC unmet need review: Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance. PubMed. 2023. PMID:37079311.

    NCCN guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. NCCN.

    Glucocorticoid receptor biology: Glucocorticoid Receptor Signaling in Cancer. PMC7694440.

    Apoptosis reference: Apoptosis. StatPearls. NCBI.

    Cortisol overview: Cortisol. StatPearls. NCBI.

    RECIST/PFS methodology: New Response Evaluation Criteria in Solid Tumours. PMC3107543.

    Checkpoint inhibitors in ovarian cancer: Immune Checkpoint Inhibitors in Ovarian Cancer. PMC7174922.

    PARP inhibitors: PARP Inhibitors. cancer.gov.

    Neutropenia: Neutropenia. StatPearls. NCBI.

    Patient resources: Ovarian Cancer Research Alliance | Foundation for Women’s Cancer | NCCN Ovarian Cancer Guidelines | Lifyorli Support: 1-855-439-6754

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for platinum-resistant ovarian cancer should be made in consultation with a qualified gynecologic oncologist.

  • The KRESLADI Trial Data That Just Earned the First Gene Therapy Approval for LAD-I

    The KRESLADI Trial Data That Just Earned the First Gene Therapy Approval for LAD-I

    📌 The essentials On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel, Rocket Pharmaceuticals), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I), indicated specifically for pediatric patients who lack an available HLA-matched sibling donor. The clinical basis: a Phase 1/2 trial (NCT03812263) enrolling 9 children with molecularly confirmed severe LAD-I, showing 100% HSCT-free survival at one year (95% CI 66 to 100; p less than 0.001), 0 graft failures, and sustained neutrophil CD18 expression through median 4.2-year follow-up. Results published in the New England Journal of Medicine. This is an accelerated approval based on biomarker surrogates (CD18 and CD11a expression). Confirmatory post-marketing studies are required. Rare Pediatric Disease Priority Review Voucher granted alongside approval. The boxed warning: lentiviral vector-mediated insertional oncogenesis, requiring long-term post-treatment monitoring.

    Most children born with severe Leukocyte Adhesion Deficiency Type I do not survive to their second birthday without treatment. Their white blood cells, the immune system’s first responders, lack a critical surface protein called CD18 that allows them to exit the bloodstream and reach the site of infection. Without it, bacteria and fungi go virtually unchallenged. The infections are relentless, poorly responsive to antibiotics, and frequently fatal. Omphalitis, infection of the umbilical stump, is sometimes the first sign, in a newborn just days old.

    The only curative option before March 2026 was an allogeneic hematopoietic stem cell transplant from an HLA-matched sibling donor. Most children do not have one. Transplants from mismatched donors carry substantial risks: graft failure, graft-versus-host disease, and transplant-related mortality. Some families faced a situation with no good path forward.

    On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel), the first gene therapy for severe LAD-I, indicated specifically for pediatric patients without an available matched sibling donor. The clinical trial behind it enrolled nine children. None had graft failure. All survived. The youngest were infants; all who were enrolled under age one were alive beyond age two. The data was published in the New England Journal of Medicine.

    Leukocyte Adhesion Deficiency Type I: What It Is and Why It Kills

    LAD-I is caused by biallelic (two-copy) loss-of-function mutations in the ITGB2 gene, which encodes CD18, the beta-2 integrin subunit that pairs with CD11 proteins to form integrin complexes on the surface of leukocytes. These CD11/CD18 complexes, particularly LFA-1, composed of CD11a and CD18, are what allow white blood cells to adhere to the inner walls of blood vessels and migrate through them into infected tissues. Without functional CD18, neutrophils and other leukocytes stay in circulation. They cannot reach wounds. They cannot engulf bacteria at infection sites. Infections that a healthy immune system would clear in days become life-threatening emergencies.

    Severe LAD-I is defined by CD18 surface expression below 2% of normal. At this level, even minor infections, a skin abrasion, a gum infection, the umbilical cord stump, can become life-threatening. The infection burden is compounded by delayed wound healing: without leukocyte migration, the inflammatory cascade needed for tissue repair does not function properly.

    How rare is LAD-I? The incidence of LAD-I in the U.S. is estimated at approximately 1 in 100,000 to 1 in 200,000 live births. Roughly two-thirds of affected patients have the severe form. Based on approximately 3.6 million U.S. births per year, that translates to roughly 12 to 24 new cases of severe LAD-I annually in the United States. Global prevalence is higher in regions where consanguineous marriage is more common, as LAD-I is autosomal recessive, meaning a child must inherit one mutated ITGB2 copy from each parent. In some Middle Eastern and South Asian populations, the disease burden is proportionally higher. The ultra-rarity of the disease is part of why gene therapy development has been slow: a clinical trial enrolling 9 patients represents a meaningful fraction of the total global patient population who meet enrollment criteria at any given time.

    How KRESLADI Works: Lentiviral Gene Correction of the Patient’s Own Stem Cells

    KRESLADI is an autologous gene therapy, meaning it is manufactured from the patient’s own cells, corrected in the laboratory, and returned to the same patient. This eliminates the core risk of donor-based transplantation: immune mismatch. There is no foreign tissue to reject, and no graft to mount an attack against the host.

    The manufacturing process follows a sequence of steps before the patient receives a single intravenous infusion:

    Mobilization and apheresis: The patient receives drugs (G-CSF and/or plerixafor) to mobilize hematopoietic stem cells (HSCs) from the bone marrow into the bloodstream. These CD34+ progenitor cells are then collected by apheresis, a process that filters blood through a machine and harvests stem cells.

    Ex vivo gene correction: The harvested CD34+ cells are taken to a manufacturing facility and transduced with a lentiviral vector carrying a functional copy of the ITGB2 gene. The lentiviral vector integrates into the cell genome, providing a permanent genetic correction. A back-up collection of unmodified CD34+ cells is preserved in case engraftment fails.

    Myeloablative conditioning: Before infusion, the patient undergoes full myeloablative conditioning, high-dose chemotherapy designed to eliminate the existing defective bone marrow and create space for the corrected cells to engraft. This is a significant clinical intervention and the primary source of short-term treatment-related risk.

    Infusion: The gene-corrected cells are infused intravenously in a single dose. They travel to the bone marrow, engraft, and begin producing CD18-expressing neutrophils and other leukocytes, ideally for the patient’s lifetime.

    Lentiviral vectors and insertional oncogenesis: the long-term risk to understand A lentiviral vector works by integrating a copy of the therapeutic gene into the patient’s genome, which is what makes the correction permanent. But integration is not perfectly targeted: the vector can insert near oncogenes (cancer-promoting genes), potentially disrupting their regulation. This risk is called insertional oncogenesis. Early-generation retroviral gene therapies for X-linked SCID caused leukemia in some patients, creating lasting concern about the category. Modern lentiviral vectors like the one used in KRESLADI are self-inactivating (SIN): the viral promoter that could drive oncogene expression is deleted after integration, substantially reducing this risk. The prescribing information for KRESLADI includes a formal warning for lentiviral vector-mediated insertional oncogenesis and requires long-term follow-up monitoring. No cases of insertional oncogenesis were observed in the Phase 1/2 trial, but with a median follow-up of 4.2 years in only 9 patients, long-term surveillance remains a post-marketing requirement. This is not a reason to avoid the therapy in a disease with near-certain early mortality without treatment, but it is a reason for enrolled families to maintain follow-up.

    The Phase 1/2 Clinical Trial: Nine Patients, Published in NEJM

    The trial supporting KRESLADI’s approval (NCT03812263) was an open-label, single-arm, multicenter Phase 1/2 study conducted at leading pediatric immunodeficiency centers including UCLA and Great Ormond Street Hospital in London. It enrolled 9 children with molecularly confirmed severe LAD-I (biallelic ITGB2 mutations, CD18 expression below 2% of normal) who lacked an available HLA-matched sibling donor.

    The primary endpoints were biomarker-based: neutrophil CD18 and CD11a surface expression at 12 and 24 months, used as surrogates for restored immune function. Secondary endpoints included safety, engraftment, infection events, and HSCT-free survival. Results were published in the New England Journal of Medicine.

    OutcomeResult
    Study population9 children with severe LAD-I, biallelic ITGB2 mutations, no HLA-matched sibling donor
    HSCT-free survival at 1 year100% (95% CI 66 to 100; p less than 0.001)
    Graft failures0 of 9
    Median follow-up4.2 years (range 3.6 to 5.7)
    Neutrophil CD18 expression (Month 12)Sustained increase in all 9 patients
    Neutrophil CD18 expression (Month 42)Sustained in all 7 patients with available data
    Neutrophil CD11a expression (Month 12)Median 45% (range 18 to 75)
    Neutrophil CD11a expression (Month 24)Median 39% (range 17 to 65)
    Patients enrolled below age 1 yearAll alive beyond 2 years of age
    Treatment-related serious adverse eventsNone reported
    Insertional oncogenesis casesNone observed (ongoing monitoring required)

    Source: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

    The 100% HSCT-free survival figure warrants careful interpretation alongside the confidence interval (66 to 100%). With only 9 patients, the lower bound of that confidence interval means the true survival rate could theoretically be as low as 66%, which is not a negligible uncertainty. The FDA’s accelerated approval based on biomarker data rather than confirmed long-term clinical outcomes reflects this: the agency considered the surrogate endpoints (CD18 and CD11a expression) sufficiently likely to predict clinical benefit given the biological coherence and the disease’s natural history, while requiring confirmatory data through post-marketing studies.

    What the 4.2-year median follow-up confirms is durability of the biomarker response: all 7 patients with data available at month 42 maintained sustained neutrophil CD18 expression. The correction appears stable across the observation period, which is among the longest available for any lentiviral hematopoietic gene therapy in a primary immunodeficiency.

    Vinay Prasad, MD, MPH, Chief Medical and Scientific Officer and Director of the FDA Center for Biologics Evaluation and Research, stated at the time of approval that today’s accelerated approval provides a breakthrough treatment for pediatric patients with severe LAD-I, the first FDA-approved gene therapy to treat this disease.

    KRESLADI vs. Allogeneic HSCT: Understanding the Comparison

    The most meaningful clinical comparison for KRESLADI is not placebo. In a disease with near-certain early mortality, a placebo-controlled trial would be unethical. The relevant comparison is allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor, the only prior curative approach.

    FeatureKRESLADI (gene therapy)Matched sibling HSCT
    Donor requiredNo, uses patient’s own cellsYes, HLA-matched sibling
    AvailabilityAll eligible patients without matched siblingApproximately 25 to 30% of patients have matched sibling
    GVHD riskNone (autologous)Significant, especially with mismatched donors
    Graft failure risk0 of 9 in trialHigher with mismatched; lower with matched sibling
    Conditioning requiredYes, full myeloablativeYes, myeloablative or reduced-intensity
    Insertional oncogenesis riskSmall but real (lentiviral vector)None
    Long-term follow-up dataMedian 4.2 years (n=9)Decades; large registry data available
    Regulatory statusFDA accelerated approval (March 2026)Standard curative approach (first-line when donor available)

    The comparison highlights that KRESLADI is approved specifically for the gap population, those without an available HLA-matched sibling donor. It does not replace matched-sibling HSCT, which remains the standard approach when a donor is available. For families without that option, gene therapy now provides a curative path that did not previously exist.

    The ongoing clinical evolution of HSCT is also worth noting. Haploidentical transplantation, using a partially matched donor such as a parent, is increasingly feasible through improved graft manipulation techniques and is being evaluated as an alternative for patients without matched siblings. The availability of KRESLADI creates an additional option alongside these evolving transplant approaches, giving clinicians and families more to consider.

    Safety: What to Know Before Treatment

    No treatment-related serious adverse events were reported in the Phase 1/2 trial, a notable finding given the severity of the conditioning regimen required. Most adverse reactions reflected the expected effects of myeloablative conditioning rather than the gene therapy product itself.

    Common adverse reactions in the trial population included: mucositis, upper respiratory tract infection, viral infection, febrile neutropenia, skin lesions, nausea and vomiting, rash, pyrexia, device-related infection, decreased blood counts (hemoglobin, platelets, neutrophils, leukocytes), and elevated liver enzymes (AST, ALT).

    The prescribing information includes formal warnings and precautions for:

    • Serious infections: susceptibility increases during the myeloablative conditioning period before engraftment is established
    • Veno-occlusive disease (hepatic VOD): monitor liver function tests during the first month following infusion
    • Neutrophil engraftment failure: defined as failure to achieve absolute neutrophil count of 500 cells per microliter or higher by Day 43; back-up unmodified CD34+ cells are preserved in case rescue is needed
    • Delayed platelet engraftment
    • Lentiviral vector-mediated insertional oncogenesis: long-term monitoring required
    • Hypersensitivity reactions

    What Treatment Involves: The Full Patient Journey

    For families whose child has been diagnosed with severe LAD-I and lacks an HLA-matched sibling donor, the path to KRESLADI involves a structured sequence of steps that requires specialized care at a qualified treatment center.

    Genetic confirmation first

    KRESLADI is indicated specifically for patients with severe LAD-I due to biallelic variants in ITGB2 confirmed by molecular testing, with CD18 expression below 2% of normal. Clinical diagnosis alone is not sufficient for eligibility. Genetic testing confirming the ITGB2 mutations is required.

    Specialized treatment center

    KRESLADI will be administered only at qualified treatment centers with experience in bone marrow transplantation and gene therapy. The manufacturing process, including mobilization, apheresis, ex vivo gene correction, and back-up cell preservation, requires institutional infrastructure that is not available at all pediatric centers. Rocket Pharmaceuticals indicated it plans a measured rollout to ensure quality and safety at launch.

    Timing matters

    The trial enrolled children as young as infants. Outcomes in LAD-I gene therapy, as in most gene therapies for primary immunodeficiencies, are generally better when treatment is given before significant infection-related damage has accumulated. Families who receive a diagnosis of severe LAD-I should contact a specialized immunodeficiency center promptly to discuss evaluation and next steps, rather than waiting for a clinical crisis.

    Regulatory designations

    KRESLADI received multiple FDA designations supporting its development:

    With approval, Rocket Pharmaceuticals received a Rare Pediatric Disease Priority Review Voucher, a transferable regulatory instrument that entitles the holder to priority (6-month) FDA review for a future NDA or BLA. PRVs have historically traded in the $100 to $150 million range. Rocket may use the voucher for a future program or sell it; either way, it represents a financial mechanism designed to incentivize rare pediatric drug development.

    For related coverage of other rare pediatric disease FDA approvals in 2026, see our posts on the first gene therapy for genetic deafness approved under the Rare Pediatric Disease PRV program, the UX111 gene therapy BLA for Sanfilippo syndrome now under FDA review, and the approval of navepegritide (YUVIWEL) for achondroplasia in children.

    For families whose child has been diagnosed with severe LAD-I or who are under evaluation for a primary immunodeficiency presenting with recurrent severe infections in infancy, the most important first step is early referral to a center with expertise in primary immunodeficiencies and gene therapy. The Immune Deficiency Foundation maintains a directory of immunodeficiency specialists and can connect families with clinical expertise. For questions about KRESLADI specifically, Rocket Pharmaceuticals’ medical affairs team and information on the treatment program are available through their website. The confirmatory post-marketing studies will build the long-term evidence base that the Phase 1/2 trial, while remarkable, cannot yet provide. Families who enroll in long-term follow-up contribute directly to that body of evidence.

    Sources

    FDA press release: FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I. FDA.gov. March 26, 2026.

    Rocket Pharmaceuticals press release: Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe LAD-I. March 27, 2026. ir.rocketpharma.com.

    FDA approval letter: BLA 125806/0 Approval Letter. March 26, 2026.

    KRESLADI prescribing information: KRESLADI (marnetegragene autotemcel) Prescribing Information. Rocket Pharmaceuticals; 2026.

    NEJM primary publication: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

    Phase 1/2 trial registration: NCT03812263. Gene Therapy for Leukocyte Adhesion Deficiency Type I. ClinicalTrials.gov.

    Pharmacy Times coverage: FDA Approves Marne-Cel, First Stem Cell-Based Gene Therapy for Pediatric Patients With LAD-I. pharmacytimes.com. March 2026.

    Rheumatology Advisor: Gene Therapy Kresladi Approved for Severe Leukocyte Adhesion Deficiency-I. rheumatologyadvisor.com. March 2026.

    BioPharm International: FDA Approval of Kresladi Expands Gene Therapy in Pediatric Rare Diseases. biopharminternational.com. April 2026.

    Disease overview: Novoa EA et al. Leukocyte adhesion deficiency-I: A comprehensive review. J Allergy Clin Immunol Pract. 2018.

    LAD-I GARD overview: Leukocyte Adhesion Deficiency Type 1. rarediseases.info.nih.gov.

    CD18 biology: CD18 integrin biology. PMC5555401.

    Lentiviral vectors: Lentiviral vectors in gene therapy. PMC6563422.

    Insertional oncogenesis: Insertional oncogenesis risk in gene therapy. PMC8709598.

    Hematopoietic stem cells: Hematopoietic Stem Cells. StatPearls. NCBI.

    Myeloablative conditioning: Myeloablative Conditioning. StatPearls. NCBI.

    Haploidentical HSCT: Haploidentical Transplantation. PMC7138706.

    HLA matching in HSCT: HLA Matching in HSCT. StatPearls. NCBI.

    Accelerated approval pathway: Accelerated Approval Program. FDA.gov.

    Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

    Patient resources: Immune Deficiency Foundation | NORD: LAD-I | Rocket Pharmaceuticals | ClinicalTrials.gov: LAD-I

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for severe LAD-I should be made in consultation with a board-certified pediatric immunologist or hematologist at a center with expertise in gene therapy and primary immunodeficiencies. KRESLADI received accelerated approval; continued approval may be contingent on confirmatory post-marketing study results.
  • Prolia Costs $2,500 a Dose. There Are Now 19 Biosimilar Competitors. Here’s What That Means for Patients.

    Prolia Costs $2,500 a Dose. There Are Now 19 Biosimilar Competitors. Here’s What That Means for Patients.

    📌 The essentials On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia (denosumab, Amgen) for all five of Prolia’s approved indications. Commercial launch expected Q3 2026. This is the 19th FDA-approved denosumab biosimilar, not the first. Several have already launched commercially in the United States with modest savings of approximately 5 to 15% below Prolia’s list price. Critical distinction for patients: PONLIMSI is approved as a biosimilar but does NOT have interchangeable designation. Only Jubbonti (Sandoz) has interchangeable status for Prolia, meaning only Jubbonti can be substituted by a pharmacist without calling your prescriber. Simultaneously, Teva announced that the FDA and EMA have both accepted regulatory filings for its proposed omalizumab (Xolair) biosimilar. This is not an approval; it is the start of review. A Prolia discontinuation warning: do not stop denosumab abruptly for any reason, including a transition to a biosimilar. Rebound vertebral fractures are a documented serious risk. Any transition must be clinician-guided.

    Osteoporosis affects an estimated 200 million people globally and is responsible for approximately 9 million fractures per year worldwide. In the United States, about 10 million adults have osteoporosis and another 44 million have low bone density, putting them at elevated fracture risk. Hip fractures in older adults carry a one-year mortality rate of up to 36%, a statistic that makes bone health a genuine life-or-death clinical priority, not a cosmetic concern.

    Denosumab (Prolia, Amgen) is one of the most effective medications available for high-risk osteoporosis. It reduces vertebral fracture risk by up to 68%, hip fractures by 40%, and nonvertebral fractures by 20% in clinical trials. It is also, without insurance, a $2,506 injection administered twice a year, making it inaccessible or unaffordable for many of the patients who need it most.

    On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia, and simultaneously announced that regulatory agencies in both the U.S. and Europe have accepted filings for its proposed biosimilar to Xolair (omalizumab), a biologic used in severe asthma, nasal polyps, and IgE-mediated food allergy. These are meaningful regulatory events, but they exist in a context that the original announcement does not capture: the denosumab biosimilar market is now crowded, savings to patients have been disappointingly modest so far, and understanding the difference between a biosimilar and an interchangeable biosimilar has real implications for whether your pharmacist can make the switch without calling your doctor.

    What Denosumab Does and Why It Is So Expensive

    Denosumab is a fully human monoclonal antibody that works by inhibiting RANKL, receptor activator of nuclear factor kappa-B ligand, a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for breaking down bone. By blocking RANKL, denosumab suppresses bone resorption, which allows bone mineral density to increase and fracture risk to fall.

    Amgen markets denosumab under two brand names: Prolia (60 mg subcutaneous injection every 6 months) for osteoporosis and bone loss from hormonal cancer therapies, and Xgeva (120 mg every 4 weeks) for preventing skeletal-related events in patients with bone metastases and giant cell tumors. The two products use the same molecule but are approved for different indications at different doses.

    The $2,500+ price per dose reflects the cost of biologic drug manufacturing. Denosumab is produced in living cells using complex, expensive processes, not synthesized chemically like a small molecule tablet. Amgen has generated approximately $2.9 billion annually from Prolia alone. Despite recent patent expirations in the U.S. and Europe opening the door to biosimilar competition, the denosumab market has yet to see the dramatic price reductions that biosimilar proponents hoped for.

    A critical clinical nuance: the rebound fracture risk on discontinuation Denosumab has a well-documented risk of rebound vertebral fractures when treatment is stopped abruptly. Because denosumab’s anti-resorptive effect reverses quickly after the drug clears the system, faster than bisphosphonates which accumulate in bone tissue, stopping denosumab without transitioning to another therapy can produce a rapid spike in bone turnover that significantly increases fracture risk in the first 12 to 24 months after discontinuation. Multiple cases of simultaneous vertebral fractures following denosumab discontinuation have been reported in the literature. Current guidelines recommend that patients stopping denosumab for any reason, including switching to a biosimilar if the transition is not managed carefully, receive bridging therapy with a bisphosphonate. This is not a biosimilar-specific concern, but it is relevant for any patient or prescriber navigating a formulary switch or change in product.

    PONLIMSI: What the Approval Is Based On

    PONLIMSI (denosumab-adet) received FDA approval on March 30, 2026, based on a totality of evidence demonstrating comparable efficacy, safety, and immunogenicity to Prolia. This evidence includes data from a randomized, double-blind Phase 3 clinical trial (NCT04729621) enrolling 332 women with postmenopausal osteoporosis, comparing denosumab-adet directly against Prolia across these endpoints.

    PONLIMSI is approved for all five indications of the reference product Prolia:

    IndicationPatient Population
    Postmenopausal osteoporosisWomen at high risk for fracture, including history of fracture or multiple risk factors; or failed or intolerant to other osteoporosis therapy
    Male osteoporosisMen at high risk for fracture
    Glucocorticoid-induced osteoporosisMen and women on long-term corticosteroid therapy at high risk for fracture
    Prostate cancer bone lossMen at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
    Breast cancer bone lossWomen at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

    The EMA granted marketing authorization for PONLIMSI in Europe in November 2025, meaning the drug had already been approved in the EU before its U.S. clearance. Teva has indicated a commercial launch in the United States is expected in Q3 2026.

    The Critical Distinction: Biosimilar vs. Interchangeable and Why It Matters for Patients

    This is the most practically important piece of information in this post, and it was absent from the original coverage of PONLIMSI’s approval.

    In the United States, there are two categories of FDA-approved biosimilars: biosimilar and interchangeable biosimilar. The difference matters at the pharmacy counter.

    BiosimilarInterchangeable Biosimilar
    FDA standardHighly similar to reference product; no clinically meaningful differences in safety, purity, potencySame as biosimilar PLUS: can be substituted without the prescriber’s involvement
    Pharmacy substitutionCannot be substituted automatically; requires prescriber authorization or new prescription in most statesCan be substituted by pharmacist without calling the prescriber (subject to state pharmacy laws)
    Benefit to payer and patientMay require step therapy or prior authorization to access lower costFormulary substitution can happen more easily, driving faster cost competition
    PONLIMSI statusBiosimilar only, NOT interchangeable (as of approval)Jubbonti (Sandoz) has interchangeable designation
    Real-world implicationPrescriber or insurer action typically neededPharmacist can swap without a call to the prescriber

    Teva’s announcement did not mention an interchangeability designation for PONLIMSI. This means that in most U.S. states, a pharmacist cannot automatically substitute PONLIMSI for Prolia based on a prescription for denosumab. A clinician or insurer action is typically required. Patients who want to access the biosimilar version may need to ask their provider to write a new prescription specifically for PONLIMSI, or navigate a formulary preference process through their insurer.

    The Denosumab Biosimilar Landscape: 19 Approvals, Modest Savings

    PONLIMSI is not entering an empty market. By the time it launches in Q3 2026, it will be one of at least 19 FDA-approved denosumab biosimilars. Eighteen were approved by the end of December 2025, with PONLIMSI the first addition in 2026. Several have already launched commercially in the United States.

    BiosimilarCompanyFDA StatusNotes
    Jubbonti / WyostSandozApproved March 2024; launched June 2025First to market; interchangeable designation; 14.5% below Prolia WAC
    Osenvelt / StobocloCelltrionLaunched July 20255 to 10% discount range reported
    Jubereq / OsvyrtiAccord BioPharmaLaunched October 2025Competitive pricing
    Enoby / XtrenboGedeon Richter / HikmaApproved; not yet launched—
    Bilprevda / BildyosHenlius / OrganonApproved; not yet launched—
    PONLIMSITevaApproved March 2026; Q3 2026 launch expectedNo interchangeability designation announced

    The savings picture has been a disappointment relative to earlier expectations. Sandoz’s Jubbonti, the first approved interchangeable denosumab biosimilar, launched in June 2025 at a list price approximately 14.5% below Prolia’s wholesale acquisition cost. Celltrion’s biosimilars entered at an estimated 5 to 10% discount. A published budget impact model in the Journal of Medical Economics projected savings of $0.59 per member per month for health plans at medium conversion rates over five years, meaningful at scale, but not the 50 to 80% price reductions that biosimilar competition drove in markets like Europe.

    Why are U.S. denosumab biosimilar savings so modest compared to Europe? In the UK, biosimilar adoption within the first year of launch routinely exceeds 90% of market share, driven by NHS tender-based procurement and institutional formulary switches. British rheumatologist Dr. Muhammad Nisar noted to Medscape that clinicians feel very comfortable with denosumab biosimilars, with great belief in their efficacy and safety. In the U.S., the market structure is fundamentally different. Amgen has kept Prolia competitively priced through rebates to pharmacy benefit managers (PBMs) and insurers. The net price paid by many payers may already be below the biosimilar list price after rebates. This perverse dynamic, in which originator rebates can make a brand-name drug cheaper to a payer than the biosimilar list price, is a structural feature of the U.S. drug market that dampens biosimilar adoption and competition. The interchangeability designation matters here too. Only Sandoz’s Jubbonti has interchangeable status for Prolia, allowing direct pharmacy substitution. The other approved denosumab biosimilars, including PONLIMSI, require prescriber action or payer-directed formulary changes to reach patients, slowing the pace of market conversion.

    The Xolair Biosimilar Filing: A Different Market, A Different Opportunity

    Teva’s simultaneous announcement that both the FDA and EMA have accepted filings for its proposed biosimilar to Xolair (omalizumab, Genentech/Novartis) is a separate and strategically distinct event from the PONLIMSI approval.

    What omalizumab is and who uses it

    Omalizumab (Xolair) is a monoclonal antibody that works by binding to free IgE, immunoglobulin E, the antibody class central to allergic responses, and blocking its interaction with IgE receptors on mast cells and basophils. By reducing free IgE levels, omalizumab prevents the downstream allergic cascade that produces symptoms in atopic disease.

    Xolair is approved in the U.S. for: moderate-to-severe persistent allergic asthma inadequately controlled by inhaled corticosteroids in patients 6 and older whose asthma is related to a perennial allergen; chronic rhinosinusitis with nasal polyps in adults; chronic spontaneous urticaria in patients whose symptoms are inadequately controlled by antihistamines; and IgE-mediated food allergies in patients 1 year and older. That food allergy indication, the most recent addition, significantly expanded the patient population that might use omalizumab.

    The market context

    Global omalizumab sales are estimated at $3.5 to $3.7 billion annually, making this a commercially meaningful biosimilar target. Regulatory filing acceptance by both FDA and EMA simultaneously means Teva’s submission was complete enough for substantive review. This is not an approval; it is the beginning of the regulatory review process. The FDA’s standard review clock for biosimilar applications is 12 months from acceptance.

    The omalizumab biosimilar market is at an earlier stage than denosumab. The omalizumab biosimilar landscape will be watched carefully by allergists, pulmonologists, and patients with severe allergic disease who currently pay thousands of dollars per year for brand-name Xolair, a cost that is a meaningful access barrier for many.

    What This Means in Practice: Guidance for Patients

    If you are currently on Prolia or another denosumab product

    Do not stop denosumab without a medical plan for what comes next. The rebound fracture risk on discontinuation is real and serious. Any transition to a biosimilar should be clinician-guided, maintaining the same dosing schedule (every 6 months for Prolia indications) and likely incorporating a bisphosphonate bridge if you stop denosumab for any reason.

    If cost is a barrier to accessing denosumab, ask your prescriber or pharmacist specifically about available biosimilar options. If your insurer’s formulary includes an interchangeable denosumab biosimilar like Jubbonti, your pharmacist may be able to substitute automatically. For non-interchangeable biosimilars like PONLIMSI, a prescriber action is required. Medicare Part B, through which administered biologics are often covered, has specific biosimilar substitution rules worth understanding with your provider.

    If you are on Xolair for allergic asthma, nasal polyps, urticaria, or food allergy

    A biosimilar is not yet available. Teva’s application is under review, and even after approval, launch timing will depend on regulatory processes and commercial decisions. Continue your current treatment as prescribed. Monitor your insurer’s formulary for updates in 2026 and 2027.

    The Gap Between Biosimilar Approval and Patient Savings

    The denosumab biosimilar story is instructive for understanding how U.S. drug pricing actually works and why regulatory approval of a biosimilar does not automatically translate to patient savings.

    When Prolia’s key patents began expiring, the expectation was that biosimilar competition would drive meaningful price reductions, as it has in Europe. Instead, 19 FDA approvals later, the most aggressive biosimilar discount achieved is about 14.5% below Prolia’s list price. The originator still commands most of the market. The structural reasons are complex: Amgen’s rebate practices, the lack of interchangeability designation for most competitors, the physician-administered nature of the injection (which keeps it under Part B rather than Part D, with different substitution rules), and the clinical hesitancy around switching patients who have been stable on a therapy that must not be interrupted without a plan.

    Flanigan et al. noted in their 2025 Journal of Medical Economics budget impact analysis that even a small discount of 5% for a biosimilar referencing Xgeva and Prolia could represent millions of dollars in savings for a health plan, with the potential for reinvestment to further expand access. Those savings are real at scale even when they feel modest at the individual patient level.

    None of this means biosimilar approvals like PONLIMSI are without value. For payers, even modest per-dose discounts multiply across large patient populations. For patients in countries with less fragmented pricing structures, competitive biosimilar availability is genuinely transformative. And building a competitive biosimilar market, however slowly, creates the foundation for the price competition that patients deserve.

    The omalizumab filing, if it leads to approval and launch, enters a somewhat less saturated biosimilar market. The recent addition of the food allergy indication has expanded the potential patient population substantially. That approval, if and when it comes, may be a more commercially differentiated moment than PONLIMSI in the already crowded denosumab space.

    For related coverage of how access and affordability are shaping the drug landscape in 2026, see our post on FDA approval of the first generic dapagliflozin, where a similar story of high list prices, biosimilar or generic entry, and the gap between approval and real-world savings is unfolding in the type 2 diabetes space.

    Sources

    Teva press release: Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair (omalizumab). March 30, 2026. ir.tevapharm.com.

    Clinical Advisor coverage: FDA Approves Teva’s Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review. clinicaladvisor.com. April 2026.

    Drug Topics: FDA Approves Denosumab-Adet as Biosimilar to Prolia. drugtopics.com. March 2026.

    Center for Biosimilars: FDA Approves Teva Biosimilar for Denosumab in Osteoporosis. centerforbiosimilars.com. March 2026.

    GaBI Online: FDA approves denosumab biosimilar Ponlimsi. gabionline.net. April 2026.

    Medscape: Two More Denosumab Biosimilars Approved in the US. medscape.com. October 2025.

    Managed Healthcare Executive: Biosimilar denosumab could save $0.59 per member per month. managedhealthcareexecutive.com. February 2026.

    Journal of Medical Economics budget impact: Flanigan J, Chaplin S, et al. A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population. J Med Econ. 2025;28(1):2027-2038. doi:10.1080/13696998.2025.2027-2038.

    PONLIMSI Phase 3 trial: NCT04729621. ClinicalTrials.gov.

    GoodRx pricing: How Much Is Prolia Without Insurance? goodrx.com.

    Rebound fracture risk: Rebound vertebral fractures after denosumab discontinuation. PMC6683162.

    Denosumab mechanism: Denosumab. StatPearls. NCBI.

    RANKL biology: RANKL in bone biology. PMC3386061.

    Hip fracture mortality: Hip fracture 1-year mortality. PMC6530614.

    FDA biosimilars explained: Biosimilar and Interchangeable Products. FDA.gov.

    FDA approved biosimilar products: FDA-Approved Biosimilar Products. FDA.gov.

    Prolia FDA approval: FDA approves denosumab for osteoporosis. FDA.gov.

    Xgeva FDA approval: FDA approves denosumab (Xgeva). FDA.gov.

    Xolair FDA approval: FDA approves omalizumab for allergic asthma. FDA.gov.

    IgE biology: IgE in allergy. StatPearls. NCBI.

    PBM market structure: Pharmacy Benefit Managers. PMC7748166.

    Bisphosphonates: Bisphosphonates. StatPearls. NCBI.

    Patient resources: Bone Health and Osteoporosis Foundation | FDA Biosimilar Products List | GoodRx Prolia pricing

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about denosumab therapy, including switching between reference products and biosimilars, should be made in consultation with a qualified prescriber familiar with the patient’s bone health history and fracture risk. Never discontinue denosumab without medical guidance.

  • Foundayo™ Is the First GLP-1 Pill You Can Take Any Time, With Anything. Here’s What the Trial Data Shows and What the FDA Is Still Waiting to Find Out.

    📌 The essentials On April 1, 2026, the FDA approved Foundayo (orforglipron, Eli Lilly) for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity, as an adjunct to diet and exercise. The approval came 50 days after NDA submission under the Commissioner’s National Priority Voucher (CNPV) program, the fastest approval of a new molecular entity since 2002. What makes it mechanistically distinctive: orforglipron is the first oral non-peptide small molecule GLP-1 receptor agonist approved for weight management, which means it can be taken once daily at any time, with or without food, with or without water restrictions. No injection. No fasting window. No 30-minute waiting window. ATTAIN-1 trial data: mean weight loss of 11.2% at 72 weeks (highest dose, 36 mg, efficacy estimand) versus 2.1% with placebo. Among patients who completed the full 72 weeks, mean weight loss was 12.4%. Self-pay pricing: $149 per month. For patients with established cardiovascular disease: oral semaglutide currently has an approved CV risk reduction indication that Foundayo does not yet have. The CV outcomes trial (ATTAIN-CVRD) is a mandated post-marketing study. Full coverage of all nine FDA post-marketing requirements: Foundayo Post-Marketing Studies Explained.

    Forty-two percent of American adults have obesity. Effective GLP-1 receptor agonist therapies have been available since 2021. And yet fewer than 1 in 10 eligible adults are actually using them, a gap driven by needle anxiety, cost, shortage-related access barriers, and the logistical friction of injectable or restrictively-administered medications.

    On April 1, 2026, the FDA approved Foundayo (orforglipron), the first GLP-1 receptor agonist for weight management that can be taken once daily at any time of day, with or without food, with or without water. No injection. No empty-stomach requirement. No 30-minute waiting window. That combination of properties is genuinely new in this drug class, and it matters most for the patients who do not currently use GLP-1 therapies despite qualifying for them.

    This post covers what Foundayo is, what makes it mechanistically different, what the ATTAIN clinical trials showed across all doses, how it compares to oral semaglutide, what the safety profile looks like, and what the FDA is still requiring Lilly to study before the full picture is known.

    Approved in 50 Days: The CNPV Program Behind the Speed

    Foundayo was approved 50 days after NDA submission, making it the fastest new molecular entity approval since 2002 and the first new molecular entity cleared under the Commissioner’s National Priority Voucher (CNPV) program. The standard FDA NDA review clock is 10 months (Priority Review) or 12 months (Standard). The CNPV program, which designates certain applications as national health priorities, compresses that timeline dramatically.

    Obesity, affecting 42% of U.S. adults and costing the healthcare system an estimated $173 billion annually, qualifies as a national priority. The speed of approval reflects both the strength of the clinical data and a regulatory policy decision that the public health benefit of broader access to effective obesity pharmacotherapy outweighs the risk of uncertainty about longer-term safety endpoints. Those uncertainties are being managed through a substantial set of post-marketing requirements, nine mandated studies, covered in depth in our companion post.

    For full coverage of all nine post-marketing requirements including the cardiovascular outcomes trial, the 15-year thyroid cancer registry, the pediatric study, the pregnancy exposure registry, and what the suicidality and alopecia studies are examining, see: Foundayo Was Approved in 50 Days. Now the FDA Wants a Decade of Safety Follow-Up.

    What Makes Foundayo Mechanistically Different From Other GLP-1 Drugs

    Every GLP-1 receptor agonist currently available, including semaglutide, tirzepatide, liraglutide, and dulaglutide, is a peptide: a short chain of amino acids that mimics the naturally occurring GLP-1 hormone. Peptides are effective, but they are destroyed by stomach acid if swallowed, which is why most GLP-1 drugs are injected. Oral semaglutide (Rybelsus, Wegovy oral) gets around this using a chemical absorption enhancer called SNAC, but the workaround requires specific conditions: it must be taken with no more than 4 oz of plain water on an empty stomach, at least 30 minutes before eating or drinking anything else.

    Orforglipron is not a peptide. It is a small molecule, a non-peptide synthetic compound small enough and chemically stable enough to survive the digestive tract and reach GLP-1 receptors without any of those constraints. No absorption enhancer needed. No fasting window. No specific water volume. No food timing restrictions. Once daily, any time, with anything.

    Why the small-molecule distinction matters beyond convenience The peptide-vs-small-molecule difference has practical implications beyond the dosing schedule. Small molecules can typically be manufactured using conventional pharmaceutical chemistry at substantially lower per-unit cost than biologics produced in living cells. This manufacturing accessibility is one reason orforglipron is priced at $149 per month for self-pay patients, already lower than the list prices of injectable semaglutide and tirzepatide products. Small molecules also do not require refrigeration, which means no cold-chain logistics and no concerns about storing the drug in warm environments. For patients in rural or lower-income settings, or in countries without reliable cold-chain infrastructure, this is not a trivial advantage. The trade-off, as the clinical data shows, is that the weight loss achieved with orforglipron is somewhat lower than with the highest-dose injectable GLP-1s. How much that trade-off matters depends entirely on the patient and what they need from the treatment.

    The ATTAIN Clinical Trial Program: All the Numbers

    Foundayo’s approval was based primarily on data from the ATTAIN Phase 3 program. The pivotal ATTAIN-1 trial was published in the New England Journal of Medicine in November 2025.

    ATTAIN-1: Adults without diabetes (n=3,127, 72 weeks)

    Enrolled adults with obesity (BMI of 30 or higher) or overweight with at least one weight-related comorbidity, without type 2 diabetes. Randomized to orforglipron 6 mg, 12 mg, or 36 mg daily, or placebo.

    Outcome at 72 weeksPlacebo6 mg12 mg36 mg
    Mean weight loss (efficacy estimand)2.1%7.5%8.4%11.2%
    Mean weight loss (per protocol, completer)0.9%——12.4%
    Achieved 10% or more weight loss—30.9%37.9%54.6%
    Achieved 15% or more weight loss—16.5%21.7%36.0%
    Achieved 20% or more weight loss—7.3%10.9%18.4%
    Discontinuation due to adverse events—5.3%6.8%10.3%

    Source: Wharton S et al. NEJM. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774. ATTAIN-1 (NCT05869903).

    The 11.2% mean weight loss at the highest dose, or 12.4% among those who completed the full 72 weeks of treatment, is meaningful but sits below what injectable semaglutide and tirzepatide achieve at their highest doses (approximately 15 to 17% and 20 to 22% respectively). Cardiometabolic markers improved significantly across all doses: waist circumference, systolic blood pressure, non-HDL cholesterol, and triglycerides all improved relative to placebo.

    ATTAIN-MAINTAIN: Switching from injectables

    Published December 2025, ATTAIN-MAINTAIN evaluated patients who had previously achieved weight loss on injectable Wegovy or Zepbound and then switched to oral orforglipron. The key finding: weight previously lost on injectables was maintained. Patients switching from Wegovy maintained with an average difference of 0.9 kg; those from Zepbound similarly. This positions Foundayo as a viable long-term maintenance option for patients who achieve initial weight loss on injectables and want to transition to a no-injection routine.

    Foundayo vs. Oral Semaglutide: The Head-to-Head Picture

    The obvious comparison for Foundayo is oral semaglutide (Wegovy oral), approved in December 2025, the only other oral GLP-1 therapy. The two drugs are chemically different in an important way, and weighing the data and administration differences clearly helps patients and prescribers make the right choice.

    FeatureFoundayo (orforglipron)Oral semaglutide (Wegovy oral)
    Molecule typeSmall molecule (non-peptide)Peptide plus SNAC absorption enhancer
    Food and water restrictionNone, any time with or without foodEmpty stomach, 4 oz or less water, wait 30 min before eating
    RefrigerationNot requiredNot required
    Highest-dose weight loss (non-diabetic obesity)Approximately 11 to 12% (ATTAIN-1, 36 mg)Approximately 15% at 25 mg (OASIS 1 trial)
    Head-to-head in T2D (ACHIEVE-3)Orforglipron superior on HbA1c and weight vs. 14 mg oral semaNo direct obesity head-to-head trial yet
    CV outcomes indicationNot yet: ATTAIN-CVRD trial ongoing (post-marketing requirement)Yes, based on SELECT trial
    Self-pay price$149 per monthNot yet available as standalone oral obesity prescription at time of writing
    Key drug interactionCYP3A4/P-gp inhibitor: simvastatin limit of 20 mgLess significant CYP interactions

    The cardiovascular outcomes gap is the most clinically significant difference for high-risk patients. Oral semaglutide carries an approved CV risk reduction indication (reducing major adverse cardiovascular events in overweight or obese adults with established CV disease), based on the SELECT trial. Foundayo does not currently have this indication. That data is pending from ATTAIN-CVRD, one of the nine mandated post-marketing studies. For patients with established cardiovascular disease choosing between these two oral GLP-1 options, that distinction matters.

    Who Foundayo Is Approved For

    Foundayo is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:

    • Adults with a BMI of 30 kg/m² or higher (obesity), or
    • Adults with a BMI of 27 kg/m² or higher (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea

    It is not approved for use in children, in pregnancy, or in combination with other GLP-1 receptor agonists. The diabetes indication is a separate regulatory pathway. Lilly has indicated plans to submit for a type 2 diabetes indication using ACHIEVE-4 trial data by end of Q2 2026.

    How to Take Foundayo

    Administration is straightforward by GLP-1 standards:

    • One tablet taken orally once daily, any time of day, with or without food or water
    • Tablets should be swallowed whole, not split, crushed, or chewed
    • If a dose is missed, take it as soon as possible on the same day. If the day has passed, skip the missed dose; never double up
    • No titration schedule is described in the currently approved prescribing information; discuss with your prescriber
    • No refrigeration required; standard room temperature storage

    Safety: What You Need to Know Before Starting

    Boxed warning: medullary thyroid carcinoma

    Foundayo carries a boxed warning for the risk of medullary thyroid carcinoma (MTC). This warning is a class effect shared by all GLP-1 receptor agonists, based on rodent studies showing dose-dependent C-cell tumors. In humans, after many years of GLP-1 use in millions of patients, a clear MTC signal has not definitively emerged in post-marketing surveillance. The warning remains, and the FDA is requiring a 15-year thyroid cancer registry as a post-marketing study. Foundayo is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

    Serious risks

    • Pancreatitis: discontinue if pancreatitis is suspected; do not restart
    • Severe gastrointestinal reactions: severe nausea, vomiting, and diarrhea; may require hydration support
    • Acute kidney injury: may occur in the context of dehydration from GI adverse events
    • Hypoglycemia: particularly when co-administered with insulin or sulfonylureas; dose reduction of the concurrent medication may be needed
    • Gallbladder disease: cholelithiasis and cholecystitis reported with GLP-1 use
    • Serious hypersensitivity reactions: anaphylaxis and angioedema reported with the class

    Common side effects

    The most common adverse reactions, occurring in 5% or more of patients in ATTAIN-1, were gastrointestinal: nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain. These are consistent with the GLP-1 class effect and typically occur early in treatment and improve over time. Non-GI common side effects include headache, fatigue, and hair loss (alopecia). Hair loss has been reported with orforglipron as with other GLP-1s. The FDA is requiring a formal post-marketing characterization study to understand frequency, timing, severity, and reversibility.

    The CYP3A4 drug interaction: do not overlook this

    Orforglipron inhibits CYP3A4 and P-glycoprotein. The most clinically significant interaction: patients on simvastatin should not exceed 20 mg daily while taking Foundayo. This is not a listed side effect; it is a drug-drug interaction requiring dose adjustment of the concurrent medication. Clinicians and pharmacists should review the full prescribing information for all interactions before initiating.

    Perioperative considerations

    GLP-1 receptor agonists slow gastric emptying, which increases the risk of aspiration under general anesthesia. The American Society of Anesthesiologists recommends holding GLP-1 drugs before elective procedures requiring anesthesia or deep sedation. The FDA is requiring a dedicated delayed gastric emptying post-marketing study for orforglipron. In the interim, the class guidance applies: inform your anesthesiologist that you are taking a GLP-1 drug before any procedure.

    Cost, Availability, and Access

    Patient typePrice and access path
    Commercially insured (eligible)$25 per month via Lilly’s copay assistance program
    Self-pay or uninsured$149 per month through LillyDirect pharmacy
    Medicare Part D (from July 1, 2026)$50 per month via CMS Bridge Model, first major Medicare obesity drug coverage expansion
    MedicaidCoverage varies by state; contact insurer for formulary status
    Initial availabilityLillyDirect at launch; retail pharmacy and telehealth to follow

    What the FDA Is Still Waiting to Learn

    The 50-day approval speed comes with a genuine trade-off: several important safety and long-term efficacy questions remain open. The FDA has mandated nine post-marketing studies that Lilly is legally required to complete, covering cardiovascular outcomes, liver injury, delayed gastric emptying, a 15-year thyroid cancer registry, pediatric safety and efficacy in ages 6 to 12, pregnancy and lactation outcomes, suicidality assessment, alopecia characterization, and a 5-year pharmacoepidemiology study.

    For coverage of all nine requirements and what each one means, see our companion post: Foundayo Was Approved in 50 Days. Now the FDA Wants a Decade of Safety Follow-Up.

    For related HED coverage on GLP-1 medications, see our posts on GLP-1 medications and PCOS fertility research, the FDA’s review of GLP-1 medications and suicidality reports, and Wegovy HD (semaglutide 7.2 mg) and the STEP UP trial data.

    Sources

    FDA approval announcement: FDA Approves First New Molecular Entity Under National Priority Voucher Program. FDA.gov. April 1, 2026.

    Lilly approval announcement: FDA Approves Lilly’s Foundayo (orforglipron). investor.lilly.com. April 1, 2026.

    ATTAIN-1 primary publication: Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774

    ATTAIN-1 trial registration: NCT05869903. ClinicalTrials.gov.

    ATTAIN-MAINTAIN: Lilly. Orforglipron helped people maintain weight loss after switching from injectables. December 18, 2025. investor.lilly.com.

    ACHIEVE-3 head-to-head: Orforglipron vs. oral semaglutide head-to-head Phase 3. The Lancet. February 2026.

    SELECT trial (oral semaglutide CV outcomes): Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM. 2023. doi:10.1056/NEJMoa2307563

    FDA NDA approval letter: NDA 220934 Orig1s000 Approval Letter. April 14, 2026. accessdata.fda.gov.

    Foundayo prescribing information: Foundayo (orforglipron) Prescribing Information. Eli Lilly. April 2026.

    Oral GLP-1 comparison: Two Oral GLP-1s Increase Options for Patient Care. Medscape. April 2026.

    Medicare CMS Bridge Model: CMS. CMS Bridge Model for obesity drug coverage. cms.gov.

    GLP-1 gastric emptying: Delayed Gastric Emptying and GLP-1 Receptor Agonists. PMC10183139.

    ASA perioperative guidance: American Society of Anesthesiologists GLP-1 guidance. asahq.org.

    CYP3A4 reference: CYP3A4. StatPearls. NCBI.

    GLP-1 mechanism: GLP-1 Receptor Agonists. StatPearls. NCBI.

    Semaglutide pharmacology: Semaglutide. StatPearls. NCBI.

    HED companion post: Foundayo Was Approved in 50 Days. Now the FDA Wants a Decade of Safety Follow-Up.

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Drug pricing information reflects figures at time of publication and is subject to change. Always consult a qualified healthcare provider regarding medication decisions.

  • 365 Injections a Year, or 52. Awiqli Is the First Once-Weekly Basal Insulin and the Science Behind It Is More Interesting Than the Dosing Schedule.

    📌 The essentials On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae, Novo Nordisk), the first and only once-weekly basal insulin in history, for adults with type 2 diabetes. 52 injections per year instead of 365. The clinical basis: four randomized, treat-to-target ONWARDS Phase 3 trials enrolling approximately 2,900 adults with T2D. Three of the four trials showed statistically superior HbA1c reduction with icodec versus daily basal insulin. The fourth met non-inferiority. A meta-analysis across five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003). The mechanism: insulin icodec binds reversibly to albumin via fatty acid side chains, creating a circulating reservoir that releases active insulin continuously over approximately 8 days (half-life approximately 196 hours). Why the T1D indication is absent: an earlier FDA Complete Response Letter cited the higher hypoglycemia rate in ONWARDS 6 (the type 1 trial). The March 2026 approval covers type 2 diabetes only. Critical clinical consideration: icodec’s 196-hour half-life means dose adjustments take 3 to 4 weeks to reach new steady state. Titrate conservatively, no more frequently than every 1 to 2 weeks.

    Basal insulin has been a cornerstone of type 2 diabetes management for decades. It works by providing a slow, steady background level of insulin that covers overnight glucose production by the liver and keeps blood sugar from rising between meals. For millions of people with type 2 diabetes who cannot achieve adequate glycemic control with oral medications alone, basal insulin is not optional. It is what keeps them safe.

    But daily injections are a burden. Not a small one. A patient starting daily basal insulin at age 60 faces 365 injections per year for the rest of their life. Studies consistently show that fear of injection, injection fatigue, and the daily management burden contribute to insulin omission, dose skipping, and delayed treatment initiation, all of which translate into worse glycemic control and worse outcomes.

    On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae), the first once-weekly basal insulin in history, 52 injections a year instead of 365. The clinical data behind it spans five randomized trials and approximately 4,000 patients. It shows not just non-inferiority to daily basal insulin, but in several studies, superior HbA1c reduction. Understanding how that is possible, and what the trade-offs are, requires going inside the chemistry.

    How Awiqli Actually Works: The Albumin-Binding Depot Mechanism

    Existing basal insulins, glargine (Lantus, Toujeo, Basaglar) and degludec (Tresiba), achieve their extended duration through different mechanisms. Glargine precipitates at physiological pH, forming microcrystals that dissolve slowly. Degludec forms multi-hexameric chains that dissociate gradually from the injection site. Both produce half-lives of 12 to 25 hours, sufficient for once-daily dosing.

    Insulin icodec takes a fundamentally different approach. The molecule is engineered with two fatty acid side chains that allow it to bind reversibly to albumin, the most abundant protein in blood plasma. When injected, icodec does not just sit at the injection site waiting to dissolve. It enters the bloodstream and binds to circulating albumin, which acts as a reservoir. Only a small fraction of icodec is free and active at any given time; the rest is temporarily sequestered in the albumin-bound depot. As free icodec is cleared by the body, more is released from albumin to replace it.

    The result is a half-life of approximately 196 hours, about 8 days. This is long enough that a single injection provides stable, continuous insulin coverage for an entire week, with a flat pharmacodynamic profile that avoids the peak-and-trough pattern that can contribute to hypoglycemia with shorter-acting insulins.

    Why the long half-life creates a specific clinical consideration The same pharmacokinetic property that enables once-weekly dosing also means that any dose adjustment takes longer to reach a new steady state. With daily insulin, a dose increase or decrease produces a measurable effect within 1 to 2 days. With icodec’s 196-hour half-life, it takes approximately 3 to 4 weeks to reach a new steady state after a dose change. This has a practical implication for titration: icodec should be titrated conservatively, with dose adjustments made no more frequently than every 1 to 2 weeks based on fasting blood glucose. Aggressive titration, adjusting every few days as some patients do with daily insulins, risks overshoot and delayed hypoglycemia. The prescribing information provides specific titration guidance that clinicians should review carefully. Similarly, if a patient is transitioning off icodec to another insulin, the insulin effect persists for several days after the last dose. Overlap with a new insulin must be carefully managed to avoid hypoglycemia during the transition period.

    Why This Is a Resubmission and Why Type 1 Diabetes Is Not on the Label

    The March 2026 approval is not the first time Awiqli went through FDA review. In July 2024, the FDA issued a Complete Response Letter citing two issues: concerns about the manufacturing process, and concerns about the safety of insulin icodec specifically in patients with type 1 diabetes.

    The type 1 concern is worth understanding. ONWARDS 6, the Phase 3 trial evaluating insulin icodec in T1D, showed that icodec was non-inferior to degludec for HbA1c reduction. But in T1D patients, the rate of clinically significant or severe hypoglycemia was meaningfully higher in the icodec arm than in the degludec arm. The FDA’s advisory committee voted against approval for T1D, and the agency’s concerns were reflected in the CRL.

    Novo Nordisk’s response was pragmatic: rather than try to address the T1D concerns in the resubmission, which would have required additional clinical data and further delayed approval, the company resubmitted in September 2025 for the T2D indication only, where the efficacy and safety data were consistently robust. That resubmission was approved in March 2026.

    Novo Nordisk has stated that it remains committed to exploring icodec for type 1 diabetes and plans to conduct a new clinical trial in this population. The T1D indication is not closed; it is deferred. For now, Awiqli is approved for adults with type 2 diabetes only.

    The ONWARDS Trials: What the Clinical Evidence Shows

    The FDA approval is based on four trials from the ONWARDS Phase 3a clinical program, all randomized, active-controlled, and treat-to-target in design. “Treat-to-target” means that insulin doses in both arms were titrated to achieve the same blood sugar goals, a rigorous design that tests whether the drugs perform equivalently under optimized conditions.

    TrialPopulationComparatorHbA1c reduction (icodec)HbA1c reduction (comparator)
    ONWARDS 1 (78 wk, n=984)Insulin-naive T2D on non-insulin agentsGlargine U100 (once daily)−1.55%−1.35%*
    ONWARDS 2 (26 wk, n=526)T2D switching from daily basal insulinDegludec (once daily)−0.93%−0.71%†
    ONWARDS 3 (26 wk, n=588)Insulin-naive T2D on non-insulin agentsDegludec (once daily)−1.57%−1.36%†
    ONWARDS 4 (26 wk, n=582)T2D on basal-bolus regimenGlargine U100 (once daily)−1.16%−1.18% (NI met)

    * Superior (p less than 0.001) vs. glargine U100. † Superior (p less than 0.003 to p less than 0.0007) vs. degludec. NI = non-inferiority. Source: Published ONWARDS trials in NEJM, Lancet, JAMA, Lancet Diabetes Endocrinology.

    Three of the four trials showed statistically superior HbA1c reduction with icodec compared to daily basal insulin. The fourth (ONWARDS 4, in patients already on basal-bolus regimens) met the pre-specified non-inferiority margin. A meta-analysis across all five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003) and an odds ratio of 1.51 (95% CI 1.14 to 1.99) for achieving HbA1c below 7% with icodec versus comparators.

    ONWARDS 1 also demonstrated a secondary endpoint of superior Time in Range (blood glucose 70 to 180 mg/dL) with icodec compared to glargine U100, a clinically meaningful finding given the growing emphasis on TIR as an outcome measure alongside HbA1c. Additionally, in ONWARDS 1 and 3, a higher proportion of insulin-naive patients achieved an HbA1c target below 7% without clinically significant or severe hypoglycemia with icodec versus comparators, suggesting that the once-weekly drug can deliver better glycemic control without proportionally increasing hypoglycemia burden in this population.

    Dr. Julio Rosenstock, MD, Clinical Professor at UT Southwestern Medical Center and Principal Investigator of the ONWARDS trial program, characterized the approval at the time of the FDA decision as underscoring the need for new alternative insulin options that may help patients work with their healthcare providers to determine what treatment works best for them.

    The Hypoglycemia Picture: Nuanced, Not Alarming

    Hypoglycemia is the most important safety consideration in any insulin therapy, and the icodec data requires careful interpretation rather than a headline summary.

    In insulin-naive patients (ONWARDS 1 and 3), the picture is favorable: despite achieving better HbA1c control, icodec did not generate significantly more hypoglycemia than comparators, and more patients reached target HbA1c without experiencing level 2 or level 3 hypoglycemia.

    The nuance comes in the switching studies (ONWARDS 2 and 3 for patients already on insulin). Here, numerically higher rates of clinically significant (level 2) or severe (level 3) hypoglycemia were observed with icodec compared to degludec. In ONWARDS 3, rates were 0.31 versus 0.15 events per patient-year. This difference reflects a specific pharmacokinetic challenge: when patients switch from daily to weekly insulin, there is an initial period during which the full icodec depot is being established. The prescribing information recommends initiating icodec at 20% higher than the previous total daily dose for patients switching from daily basal insulin, specifically to manage this titration period.

    The clinical alert on hypoglycemia in T2D Patients treated with Awiqli tended to have a greater incidence of hypoglycemia than daily comparators in some study arms, while in insulin-naive patients the rates were comparable or favorable. The key implication is that icodec requires more careful patient selection and titration guidance when used as a switch therapy versus a treatment initiation therapy. In T2D specifically, the clinical concern about hypoglycemia is lower than in T1D: T2D patients retain some endogenous insulin secretion and have counterregulatory responses that protect against severe hypoglycemia. The T1D population, where hypoglycemia was more concerning and drove the CRL, is not included in the current U.S. approval. For T2D, the FDA and the ONWARDS investigators judged the benefit-risk profile favorable.

    Practical Use: Dosing, Switching, and Missed Doses

    The U-700 concentration: what this means practically

    Awiqli is a U-700 formulation, 700 units per mL, compared to the U-100 (100 units per mL) that most daily basal insulins use. This higher concentration is what allows a full week’s worth of insulin to be administered in a single manageable injection volume. It means that icodec is not substitutable unit-for-unit with daily insulins: a week’s dose of icodec is roughly equivalent to 7 days of the total daily dose, not a single daily dose. Careful dose calculation is required at initiation and when switching.

    Starting doses and switching guidance

    Patient situationStarting approach
    Insulin-naiveStart at 70 units once weekly. Titrate based on fasting blood glucose, adjusting no more than every 2 weeks.
    Switching from daily basal insulinStart at 20% higher than previous total daily basal dose, given once weekly. This accounts for the accumulation phase.
    Adding to GLP-1 or oral agentsStart at 70 units weekly (same as insulin-naive). Be alert to enhanced glucose-lowering from the combination.
    Patients on basal-bolus regimensSwitch based on individual assessment; the ONWARDS 4 data supports the transition in this population.

    Missed dose flexibility: a genuine practical advantage

    One underappreciated benefit of icodec’s long half-life is missed-dose forgiveness. Because the drug accumulates in the albumin depot and releases continuously, a missed or shifted dose is less clinically consequential than with daily insulin. The prescribing information states that if a dose is missed, it can be administered up to 3 days (72 hours) before or after the scheduled day. After administration, resume the original once-weekly schedule. This flexibility directly addresses one of the practical frustrations of daily insulin, the anxiety around a forgotten or delayed dose.

    Administration

    Awiqli is administered subcutaneously once weekly on the same day each week, using the Novo Nordisk FlexTouch prefilled pen. It is available in three pen sizes: 700 units per 1 mL, 1050 units per 1.5 mL, and 2100 units per 3 mL. It must not be administered intravenously, intramuscularly, or via insulin pump, and must not be mixed with other insulin products.

    Safety: What the Prescribing Information Covers

    The safety profile of Awiqli is broadly consistent with the basal insulin class, with the nuances around hypoglycemia and titration already discussed above.

    Common adverse reactions: hypoglycemia, injection site reactions (redness, swelling, itching), lipodystrophy (skin thickening or pitting at injection sites), pruritus, rash, peripheral edema, weight gain.

    Serious risks:

    • Severe hypoglycemia
    • Serious hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and swelling of face and lips
    • Hypokalemia (low potassium, which may affect heart rhythm)

    Thiazolidinediones (TZDs): Use with pioglitazone or rosiglitazone increases the risk of fluid retention and potential heart failure exacerbation. Monitor for signs of heart failure when co-prescribing.

    Acute illness and fasting: During illness or significant changes in eating, blood glucose monitoring frequency should increase and dose adjustments may be needed. The long half-life means that missed or delayed doses are tolerated, but significant metabolic stress (surgery, serious illness) requires closer glucose monitoring.

    Not indicated for: ketoacidosis treatment, diabetic ketoacidosis, use via intravenous or intramuscular routes, or use with insulin infusion pumps.

    Why Injection Frequency Matters More Than It Might Seem

    The clinical significance of moving from daily to weekly injections goes beyond convenience. The diabetes literature on insulin adherence is consistent: injection burden is one of the leading modifiable barriers to insulin initiation and continuation. “Psychological insulin resistance,” the phenomenon in which patients delay or avoid starting insulin despite clinical need, is documented in 20 to 30% of people with T2D who are recommended insulin.

    Insulin omission is also common among those already on therapy: studies estimate that 20 to 50% of patients on daily basal insulin skip doses at least occasionally, with higher rates among those with greater injection frequency or complex regimens. Each omitted dose represents a period of inadequate glycemic coverage. Sustained omission accelerates the development of diabetes complications.

    Once-weekly dosing does not eliminate these barriers, but it substantially reduces the number of opportunities for omission and lowers the daily psychological overhead of managing insulin therapy. Whether this translates into measurably better real-world outcomes beyond what the controlled trials demonstrated will only be known from post-marketing evidence. But the mechanistic argument is sound.

    Availability and Global Status

    Novo Nordisk has indicated Awiqli will be available at U.S. pharmacies in the second half of 2026. The drug has already been approved in the European Union, Canada, Australia, Japan, Switzerland, and more than a dozen other countries, in many of those markets for both type 1 and type 2 diabetes. The U.S. approval is limited to type 2 diabetes.

    Pricing and formulary coverage have not been announced for the U.S. market at time of writing. Patients and clinicians should check with their insurance provider and Novo Nordisk’s patient support resources as the launch approaches. For patients on insulin experiencing cost barriers, the Novo Nordisk patient assistance program and the NeedyMeds database are useful starting points.

    For related HED coverage on diabetes treatment advances and access, see our posts on the FDA approval of the first generic dapagliflozin tablets and the approval of Foundayo (orforglipron), the first oral GLP-1 pill for weight management without food or water restrictions.

    Sources

    FDA approval and Novo Nordisk press release: FDA approves Novo Nordisk’s Awiqli (insulin icodec-abae), the first and only once-weekly basal insulin treatment for adults with T2D. March 26, 2026. prnewswire.com.

    HCPLive coverage: FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. hcplive.com. March 2026.

    Patient Care Online coverage: FDA Approves Once-Weekly Basal Insulin for Adults With Type 2 Diabetes. patientcareonline.com. March 2026.

    Consultant360: FDA Approves Awiqli (Insulin Icodec-Abae) as Once-Weekly Basal Insulin. consultant360.com. March 2026.

    ONWARDS 1 (NEJM): Rosenstock J et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. NEJM. 2023;389(16):1533. doi:10.1056/NEJMoa2310221

    ONWARDS 2 (Lancet Diabetes Endocrinol): Philis-Tsimikas A et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated T2D (ONWARDS 2). Lancet Diabetes Endocrinol. 2023.

    ONWARDS 3 (JAMA): Lingvay I et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive T2D: ONWARDS 3. JAMA. 2023;330(3):228-237.

    ONWARDS 4 (Lancet): Mathieu C et al. Switching to once-weekly icodec vs once-daily glargine U100 in basal-bolus insulin-treated T2D (ONWARDS 4). Lancet. 2023.

    ONWARDS 1 trial registration: NCT04508660. ClinicalTrials.gov.

    ONWARDS 2 trial registration: NCT04771052. ClinicalTrials.gov.

    ONWARDS 3 trial registration: NCT04832711. ClinicalTrials.gov.

    ONWARDS 4 trial registration: NCT04835493. ClinicalTrials.gov.

    Awiqli prescribing information: Awiqli (insulin icodec-abae) injection 700 units/mL. Novo Nordisk. 2026.

    ADA Standards 2026: American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2026. Diabetes Care. 2026;49(suppl 1).

    Time in Range reference: Battelino T et al. Clinical targets for CGM data interpretation: recommendations from the international consensus on time in range. PMC6240448.

    Insulin adherence literature: Insulin Adherence and Injection Burden in T2D. PMC7716091.

    Basal insulin overview: Basal Insulin. StatPearls. NCBI.

    Albumin physiology: Albumin. StatPearls. NCBI.

    Hypoglycemia: Hypoglycemia. StatPearls. NCBI.

    Hypokalemia: Hypokalemia. StatPearls. NCBI.

    Diabetic ketoacidosis: Diabetic Ketoacidosis. StatPearls. NCBI.

    Diabetes complications: Preventing Diabetes Complications. NIDDK.

    Patient resources: Novo Nordisk patient support | NeedyMeds | ADA Standards of Care | CDC Diabetes

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Insulin therapy requires individualized dosing and monitoring. Any changes to insulin regimen should be made in close consultation with your diabetes care provider.